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The work presented in this dissertation is of the development and validation of an 
intraoperative neural stimulator and recording system for use in deep brain stimulation (DBS) 
surgeries.  Intraoperative targeting systems provide neurosurgeons with raw electrophysiological 
data through microelectrodes used for determining location in the brain.  Typical analysis of 
these signals is subjective and heavily dependent on experience and training.  There are 
significant deficits to the available targeting systems, limiting the use in both clinical and 
research applications.  This intraoperative data acquisition system (IODA) is capable of 
recording electrophysiological signals in a wideband frequency range.  It also has the ability to 
stimulate with standard and custom stimulation parameters used for targeting and clinical 
efficacy of DBS on targeted locations in the brain. 
The system was validated with three different applications demonstrating the flexibility 
and necessity of IODA.  The first, a clinical application, illustrated the improvement IODA had 
on the targeting accuracy of DBS leads in the subthalamic nucleus (STN) over current targeting 
methods.  IODA’s navigation system showed microelectrode probe locations to be significantly 
closer to final DBS lead positions, 2.33 mm ± 0.2 mm  P = .01,  compared to the planned 
trajectory position, 2.83 mm ± 0.2 mm.  IODA was also validated with a clinical science 
application attempting to resolve a highly contested topic, the location of the most optimal 
stimulation site for chronic DBS of the STN.  Beta oscillations of local field potentials (LFP) 
recorded through IODA enabled the confirmation of previous findings for optimal sites of 
stimulation to be both, sites of peak beta activity and the dorsal border of the STN.  With 
IODA’s precise targeting, we found sites of optimal stimulation were not different from the 
dorsal border of the STN when trajectories were lateral of the STN midpoint, 0.35 ± 1.43 mm, P 
= .51, and were not different from peak beta hypersynchrony when trajectories were medial of 
the STN midpoint, -0.36 ± 1.6 mm, P = .57.  Finally, we confirmed recent findings of STN 
involvement in movement inhibition through a basic science application.  Through wideband 





suggesting increased activation in the theta, alpha, and beta bands of the LFP in response to 
movement and movement inhibition cues.  We also confirmed that single unit activity in these 
recording locations within the STN responded with significant decreases in firing rates in 
response to inhibition cues, P < .001. 
Through in depth experimentation using IODA we have validated the utility and 
adaptability of this system for use within DBS surgeries.  There is significant potential for use of 
IODA outside of DBS in other surgical procedures requiring precise neural targeting.  
Additionally there are many applications of IODA for use in research for other 
neurodegenerative disease including Essential Tremor and Depression.  The use of this system 
has enables neurosurgeons to reduce surgical time, risk, and error for DBS procedures and made 
entry easier for those less experienced in this procedure.  The novel system described in this 
work enables neurosurgeons, electrophysiologists, and researchers to significantly improve 
clinical efficacy of DBS and the understanding of physiological effects of neurodegenerative 









Chapter 1 : Introduction 
 
 
In-vivo analysis of a living human brain is a rare opportunity usually only achieved 
during clinical neurosurgery.  Only during selective types of surgery, specifically Deep Brain 
Stimulation (DBS) surgery, can we attempt to understand the circuitry and function of different 
brain structures in humans.   DBS is the application of voltage or current at set frequencies and 
amplitude to a specific location in the brain via an implanted electrode.  The surgery is currently 
approved by the FDA for the treatment of Parkinson disease and Essential Tremor as an effective 
method for the control of primary motor control symptoms of both diseases.  Given the nature of 
DBS, a brief window of access is possible to attain data through probes while the patient is 
conscious.  Intraoperative analysis on living human brains requires sophisticated electronics 
which can record and stimulate from within the brain.  The most sophisticated commercially 
available systems can only provide limited recording and stimulation capabilities with little 
flexibility in varying the parameters of each capability.  These systems were also designed to 
assist in clinical assessments of DBS surgeries and were not intended to explore potential 
improvements to the surgery or assist in answering fundamental questions regarding the brain.  
We propose to develop an intraoperative data acquisition (IODA) system that can record and 
stimulate neural tissue with the ability to control the parameters of both to explore the effects of 
DBS.  The system will be applied to specific structures in the brain during DBS surgeries so we 
can objectively measure the effects of varying DBS parameters on these brain structures.  Our 
goal is to use IODA to investigate improvements in DBS therapy and to explore clinical science 
research of the brain. 
Aims 
 In order to ensure the functionality and use of this system, we propose three applications 
of validation:  1) clinical application of the system, 2) clinical science application, and 3) basic 





 The first application of IODA is to test its functionality as a surgical navigation tool 
during DBS procedures.  We hypothesize that using IODA to collect microelectrode recording 
data and high resolution imaging data; IODA can provide more precise intraoperative electrode 
location compared to current methods. Additionally IODA can enable neurosurgeons to reduce 
surgical operating time, risk, and error.  
 The second application utilizes the system’s wideband recording to investigate optimal 
stimulation sites within the subthalamic nucleus region for DBS electrodes as they relate to the 
beta frequency band of local field potentials.  This has been a widely contested topic in recent 
studies and using IODA with high resolution imaging we hypothesize that sites of optimal 
stimulation and beta hypersynchrony are spatially dependent with respect to the STN. 
 The third validation application of IODA is to integrate intraoperative patient testing with 
microelectrode recordings to draw basic science conclusions regarding the nature of the 
subthalamic nucleus in Parkinson’s disease.  We hypothesize that recording single unit and local 
field potential activity from the STN of patients performing a motor movement task, we can 
confirm recent findings regarding the effects of movement and inhibition to movement in various 
frequency bands of the STN.   
Background 
Deep Brain Stimulation 
Deep Brain Stimulation is the application of electrical current to structures of the brain 
through implanted electrodes connected to a pulse generating source.  DBS was a major step 
forward for the treatment of such diseases as Parkinson's and Essential tremor which were 
previously treated using ablative techniques.  DBS offers similar behavioral effects as lesioning 
with the advantages of being adjustable and reversible.1  However the full physiologic 
mechanism underlying the effects of DBS are still not well understood.      
DBS surgeries are performed under local anesthetic so patients can remain conscious and 
alert for stimulation testing to measure symptom improvements.  Patients are not sedated because 
the effects of general anesthesia have been shown to disrupt the firing patterns in the sensory 
motor network, making intra-operative testing difficult and potentially inconclusive.2  Targeting 
of structures in the brain is done with a combination of technologies and methods.  The 





trajectory for the implant of the DBS electrode.  Using a microelectrode (MER) prior to 
implanting the DBS electrode, the neurosurgeon and attending electrophysiologist determine 
locations and structures in the brain by monitoring neural signals recorded from the MER probe 
through audio and visual displays from the signal.3 
Neurodegenerative Diseases 
Parkinson's disease (PD) is a debilitating neurodegenerative disorder characterized by 
motor symptoms including tremor, rigidity, and bradykinesia that affects the basal ganglia.  The 
basal ganglia are a network of nuclei associated with voluntary motor control.4  The network is 
made up of the striatum, global pallidus (GP), thalamus, substantia nigra (SNr), and the STN.  
The current model for the pathways of the basal ganglia involves a direct and indirect pathway.  
The direct pathway connects the striatum to the GPi to the motor thalamus. The direct pathway is 
associated with excitatory dopamine receptors known as D1 receptors.  Neurons with D1 
receptors project from the striatum to excite an inhibitory output from the GPi to the thalamus.  
The inhibitory output from the GPi causes a dis-inhibition of motor thalamus firing rate, thus 
increasing the firing rate of its cells and reducing the inhibition of initiated movement.5  The 
indirect pathway in the basal ganglia is believed to be ultimately regulated by the STN.5  The 
indirect pathway is associated with neurons containing inhibitory dopamine receptors referred to 
as D2 receptors.  Neurons with D2 receptors project from the striatum to the GPe causing a dis-
inhibitory output to the STN.  The STN is therefore disinhibited and its cells increase firing, 
leading to the inhibitory activation of the GPi and SNr.  Both the GPi and SNr inhibit the 
thalamus thus reducing the excitatory thalamic input to other motor areas through the motor 
cortex.  The indirect pathway is believed to inhibit unwanted movement.5 
 As Parkinson’s disease progresses, motor symptoms worsen and the side effects from 
medication become more prevalent.  PD is thought to affect both the direct and indirect pathway 
through the depletion of dopamine.   The depletion of dopamine in the direct pathway effects D1 
receptors which cause the pathway to be underactive, decreasing the firing of the thalamic 
neurons and inhibiting movement.  In the indirect pathway, dopamine depletion affects D2 
receptors causing an overactive inhibitory signal in the GPi believed to be responsible for rigidity 
and akinesia symptoms of PD.5  DBS surgery becomes an option for those patients whose quality 





associated with higher doses of PD medication..6, 7  DBS surgery for PD is typically targeted for 
the stimulation of the STN, GPi, or the VIM of the thalamus depending on the primary symptom 
of the individual patient.8  However the STN is generally targeted since it has been shown that 
stimulation in the STN inhibits the overactive inhibitory signal allowing the STN to increase 
firing of its cells.9 
 Essential Tremor (ET), the most common form of pathologic tremor, is a debilitating 
neurodegenerative disorder.  Similar to PD, ET can be treated with medication for tremor 
symptoms.  However as the disease progresses quality of life is markedly decreased due to side 
effects from higher doses of medication to control for an increase in symptom intensity.  DBS 
surgery for ET typically targets the VIM of the thalamus for stimulation as it has been shown to 
control 70% to 90% of tremor in ET patients.5, 10 
 Significant research has been done in the basal ganglia to better understand the motor 
pathway.  Single unit recordings and Local Field Potentials (LFPs), signals which are the 
measure of electrical activity from tissue near the recording source, have been used to explain the 
function and activity of different components in the pathway.    
Specifically in the STN, LFP activity has been investigated to understand the effects of 
stimulation during DBS on the motor pathway.11  Increases in the alpha band of the LFP, 1-7Hz, 
in the STN during stimulation was shown to correlate with improved symptom response.  This 
responses is in the LFP is believed to be how DBS stimulation helps to normalize STN 
hyperactivity in patients with PD.11  LFP activity in the STN has also been used to study the 
characteristics of movement in patients with PD.12, 13  Single unit recording has also shown 
feasible in the STN using microelectrodes (MER).  Single unit recordings are essential to 
determine detail, which cannot be drawn from LFPs, regarding the structure of interest.  Single 
unit data has been used to characterize the role the STN has in patients with Dystonia by 
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Objective:  Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an effective 
therapy for Parkinson’s disease (PD).  Microelectrode recording (MER) is typically used for 
intraoperative targeting of the STN.  Commercial systems used for intraoperative targeting are 
limited in functionality and features.  The aim of this work is to develop a system capable of 
providing enhanced clinical and research functionality for users during DBS surgeries.    
Method:  We developed a targeting system using FDA approved components to record and 
stimulate neural tissue during DBS.  We validated intraoperatively recorded signals with 
published findings of DBS research and commercially available targeting systems.  We also 
demonstrated the extended capabilities in stimulation profiles, user interface, and integration 
with DBS research.  
Results:  We used our intraoperative data acquisition (IODA) system in over 75 DBS surgeries.  
We validated capabilities for wideband recording, stimulation, and research applications with 
physiologic and clinical findings.  We also validated the use of magnetic resonance imaging 
(MRI) as a valuable interface for system users.   
Conclusion:  We present a novel system for use intraoperatively for data acquisition and neural 
stimulation during DBS procedures.  This system is capable of providing necessary information 
for neurosurgeons and electrophysiologists to perform standard electrophysiological analysis for 
target localization as well as DBS research. 
Clinical Impact: This system can be used for both clinical and research applications during DBS 
cases.  The system can potentially enable neurosurgeons that are not specialty trained to perform 







Deep brain stimulation (DBS) is a well-established surgical therapy for Parkinson’s disease [1].  
Chronic bilateral high-frequency stimulation of the subthalamic nucleus (STN) alleviates the 
motor symptoms of Parkinson’s disease.  Often, intraoperative confirmation of the STN location 
is performed through microelectrode recording (MER) [2-5].  MER signals enable neurosurgeons 
and electrophysiologists to determine the location of the MER probe relative to the STN target 
intraoperatively using traditional electrophysiological analysis [6]. 
During surgery, MER signals are digitally converted for display and audio analysis using 
commercially available neuromodulation targeting systems.  These systems are designed 
primarily for experienced clinical users with a technical understanding for neural signal 
modulations and stimulation.  Most available targeting systems are limited in recording 
frequency range, compatibility with existing DBS equipment, integration of research tasks, and 
stimulation capabilities.  Intraoperative MER analysis uses the high frequency band (HFB), 
typically 500 Hz to 2 kHz, for STN targeting [6-10]. However, there has been significant 
research in the local field potential (LFP) signals, typically 1Hz to 250 Hz, role in 
neurodegenerative diseases [11-18].  The available targeting systems offer the ability to record 
HFB signals from MER but not LFP, thus limiting the use of these systems in DBS research. 
 We present an intraoperative data acquisition (IODA) system for targeting and 
neuromodulation for DBS procedures.  The system is capable of both clinical and research tasks 
because it can record frequencies in a wideband range that includes HFB and LFP signals.  
IODA also has the ability to replicate standard stimulation profiles used by DBS devices as well 
as apply custom stimulation profiles for DBS research.  The system is able to integrate with 
existing DBS equipment, accessories, and experimental research tools.  Additionally, we have 
integrated magnetic resonance imaging (MRI) into IODA to create an alternative primary display 
for a more intuitive use of targeting systems.  By providing a simpler and more intuitive interface 
for IODA, we aim to create a system that can be used by neurosurgeons interested in DBS but 







IODA was designed for both intraoperative recording and stimulation of brain tissue.  We 
integrated FDA approved components for signal amplification and electrical stimulation through 
microelectrodes with custom software.  Specifications were determined through physiological 
requirements for signal recording and analysis as well as user requirements (Table 2.1).   
System Specifications 
 Required Specification 
Range 
IODA Specification Range 
MER Probe Impedance 500 kOhm to 2MOhm 500 kOhm to 2MOhm 
System input Impedance  1MOhm 100MOhm 
Sampling frequency >24kHz 1 Hz – 52kHz 
Signal Filtering >300Hz 1Hz – 8kHz 
Signal Gain 1 – 100,000 100-1,000,000 
High Frequency Band 300Hz – 5kHz 300Hz – 5kHz 
LFP <250Hz <250Hz 
Noise Floor <10uV <5uV 
Stimulation waveform Square Wave Square, triangle, custom 
Stimulation frequency 1Hz – 300Hz 1Hz – 300Hz 
Stimulation pulse width 10 microSec – 1 sec 10 microSec – 1 sec 
Stimulation Amplitude 0V – 10V 0V – 10V, 0mA – 10mA 
Graphical User Interface Raw signal view, Stim, motor, 
and filter control 
Raw signal view, Stim, 
filter, volume, motor, MRI 
view, patient tasks, and file 
writing controls 
Table 2.1: The system specifications for IODA and the required specifications based on physiological 
and user needs. 
Microelectrode Recording Probe 
The microelectrode recording (MER) probe is used to acquire neural signals during DBS 
surgery.  In our surgical setup, the probe is made of tungsten and stainless steel (microTargeting 
Electrode, FHC; Bowdoin, ME).  The probe tip is 40 micrometers in diameter and the electrode 
shank is 250 micrometers in diameter.  The electrode is configured for differential recording 
using the probe tip and the reference ring set 1 millimeter apart.   The impedance of these MER 
probes range from 500 kOhms to 2MOhms.  A low MER impedance is critical for stimulation in 
both micro and macro settings.  When applying voltage controlled stimulation the current 
delivered to the intended neural tissue is dependent on the impedance of the electrode it passes 
through.  A high impedance electrode reduces the energy delivered to the neural tissue and thus 






The wideband signal specification we used is based on current signal analysis methods 
for neural signals.  Traditionally, intraoperative electrophysiological signal analysis requires high 
frequency signals usually between 300 Hz and 5 kHz.  This frequency band enables 
neurosurgeons and electrophysiologists to monitor neuronal background activity and single unit 
firing changes as the MER probe is advanced in the brain.  This range is primarily used to 
identify DBS targets such as the subthalamic nucleus (STN) for Parkinson’s disease and the 
ventral intermediate nucleus (VIM) of the thalamus for patients with Essential Tremor.  These 
structures have signature firing patterns and are identifiable using classic electrophysiological 
acoustic analysis.  
The local field potential (LFP) signal is generally considered to be useful for 
understanding integration of various structures and local neuronal activity in recording areas.  
The LFP is typically considered to range from 1Hz to 250Hz.  Within the LFP frequency range 
there are multiple smaller bands considered to be critical in the communication between different 
brain structures and regions.  Namely, the beta band (13-30Hz) is considered to be of significant 
importance in the understanding of neurodegenerative diseases such as Parkinson’s. 
Noise Floor 
The noise floor of a targeting system must be low and well controlled in order to maintain 
a good signal to noise ratio.  Noise levels in surgical environments are difficult to control for due 
to excessive electrical interference from various surgical equipment including 
electrocardiography (EKG) monitors, intraoperative CT imaging systems, surgical lights, 
ultrasound systems, and cauterizing equipment.  These electrical interferences usually affect and 
corrupt low frequency signal recording.  It is for this reason most commercially available 
surgical recording platforms only record high frequency signals.  Typically, neuronal spikes have 
amplitudes ranging from 50 µV to 150 µV [6, 8] and LFP signals are on the order of magnitude 
of 10 µV [15].  A noise floor of at least 10 µV is necessary for capturing LFP activity during 






The stimulation of neural tissue is the premise for the beneficial effects of DBS.  
Although there is little evidence for a definitive physiological explanation of high frequency 
stimulation in the brain, the effects are well documented.  The clinical long term stimulation 
settings for each patient are determined by neurologists, but are bounded by device limitations.  
Currently, DBS devices have a fixed waveform, square-wave, with variable frequency, pulse 
width, and amplitude ranges.  The waveform can range between 10 Hz to 300 Hz stimulation 
frequency, 10 µseconds to 1 second pulse width, and range in amplitude between 0 volts and 10 
volts. 
Graphical User Interface 
The IODA GUI was designed to provide a traditional electrophysiological view of neural 
signals as well as more intuitive views using MR imaging.  Most electrophysiological systems 
depict raw neural signals recorded from MER probes as the primary view.  Typical systems 
integrate amplifiers, filters, motor controls, volume, and stimulators into the GUI and provide the 
user control over each of these parameters.   
System Architecture 
IODA has been built to interface in the operating room with standard equipment and tools 
used for DBS surgeries pertaining to movement diseases.  Figure 2.1 diagrams the overall system 






Figure 2.1: IODA Architecture includes amplifer and headstage interface for probes, data acquisiton card 
for analog to digital conversion of signal, probe depth controller, computer for realtime analysis and 
display, and speaker for audio from neural recording. 
The system is comprised of seven major components.  The pre-amplifier headstage (1) 
interfaces with MER probes to capture raw unfiltered differential signals from the patient using a 
disposable shielded cable (D360 Isolated Patient Amplifier System; Digitimer, London, 
England).  The headstage has 8 available channels each with an impedance of 100 MOhms.  The 
headstage amplifies the neural signal with a gain of 100 prior to passing the signal to the 
amplifier unit (2) where filtering and further amplification is applied.  For our clinical use, the 
amplifier applied a bandpass filter from 1Hz to 8 kHz and a gain of 10 for a total signal gain of 
1000.  The amplifier is capable of low-cut, notch, and high-cut filtering using a dynamic range of 
filter frequency values.   
Once filtered, the analog signal is digitally converted using the data acquisition card 
(DAQ) (3) (Model DT9837A, Data Translation; Marlboro, MA).  The DAQ is capable of 
sampling analog signals from 1Hz – 52 kHz with 24bit resolution with each analog input having 
an impedance of 1MOhm.  For our clinical use, the DAQ sampled the analog signals at 30 kHz 
to ensure single unit neuronal firing could be recorded without loss.  The signal was displayed 
and digitally filtered further using a commercially available computer (4) (Precision T5500, Dell; 





Digital filtering was performed for intraoperative audio monitoring (5) of the high frequency 
band signal (300 Hz – 2 kHz) used for electrophysiological monitoring.  The computer is also 
connected with the microTargeting Controller (MTC) which integrates with the motor that 
advances the MER probe in the brain (microTargeting Controller, FHC; Bowdoin, ME).  The 
MTC is capable of sub-millimeter movements of the probe and provides the depth of the probe in 
the brain.  
The system is also capable of stimulation through MER probes.  The DAQ output is 
connected to the constant current stimulator (7) (DS4, Digitimer).  This stimulator ensures 
intended amounts of current are applied to neural tissue by varying the required voltage based on 
measured impedance.  This is different from all available stimulating platforms which are 
constant voltage based stimulators which cannot control for applied energy.  The IODA 
stimulator is able to generate voltages of ± 48 V with output ranges from 1 µA to 10 mA.  
Stimulation profiles are sent from the computer to the DAQ which converts the digital signal to 
analog and passes the signal to the stimulator.  The stimulator is isolated and applies current 
stimulation directly to the MER probe via the shielded cables. 
Results 
 
We benchmarked are system capabilities and features with the Guideline 4000 (FHC; 
Bowdoin, ME) for high frequency recording, micro stimulation (1µV -100 µV), and macro 
stimulation (1 mV -10 mV).  We used previously published methods of signal analysis on 
recorded LFP signals and compared our results to recent studies in order to ensure wideband 
recording capabilities of IODA [19, 20].  In addition we demonstrated IODA’s ability to create 
customizable stimulation waveforms for research purposes and a more intuitive GUI. 
Wideband Signal Recording 
Figure 2.2 shows a brief recording of the HFB signal from the right STN of a Parkinson’s 
disease patient undergoing DBS treatment.  An individual spike had amplitude of 115 µV; which 
was consistent with physiological STN neuronal spiking amplitudes.  The signal was recorded 
differentially with a 1 MOhm impedance MER probe, analog filtered between 1 Hz and 8 kHz, 






Figure 2.2: A filtered signal recorded from within the STN of a Parkinson disease patient using IODA. 
This recording was captured using a microelectrode at a fixed depth.  The average amplitude of this 
recorded unit was 115 µV. 
 Figure 2.3 illustrates a Gabor power spectrogram of the beta band recorded from LFP 
signals in the STN of a Parkinson’s disease patient.  The signal was recorded differentially with a 
1 MOhm impedance MER probe, analog filtered between 1 Hz and 8 kHz, amplified with a gain 
= 100, sampled at 30 kHz, then downsampled to 500 Hz and digitally filtered from 5 Hz to 30 
Hz.  The method for LFP analysis and plotting is previously described [19, 20].  There is 
significant activity in the theta and beta frequency range, consistent with recent studies showing 
power intensities of the LFP signal in the STN. 
 
Figure 2.3: A spectrogram of 5 Hz to 30 Hz power in the LFP signal recorded from the STN of a 
Parkinson disease patient using IODA.  Power intensities are normalized for the frequency band.  





Noise Floor Amplitude 
Figure 2.4 shows the noise floor of IODA.  The signal was generated without any neuronal 
recordings or other signal sources.  The average baseline for noise in our surgical setup using 
IODA was 5 µV. 
 
Figure 2.4: The baseline noise for the IODA system turned on and not connected with adjunctive 
components is 0.5 µV. 
Stimulation Capabilities 
IODA is capable of providing the standard square wave stimulation waveform with 
varying pulse widths, frequencies, and amplitudes.  Figure 2.5 shows the standard square wave 
pulse generated from the Medtronic 8840 external stimulation and IODA at amplitude of 2 V, 






Figure 2.5: Medtronic 8840 (Blue plot) vs IODA stimulator (Green plot) at 2Volts 130 Hz square wave 
with 60 µs pulse width.  X-axis represents measured voltage and Y-axis represents samples recorded. 
Medtronic 8840 yielded 2V output, IODA stimulator averaged 2V output. 
IODA is also capable of customizable stimulation profiles that vary waveforms, 
frequencies, pulse widths, and amplitudes.  Figure 2.6 shows various stimulation profiles of 
IODA. 
 
Figure 2.6: Examples of IODA custom stimulation profile capability.  A) A single square wave pulse at 
130 Hz, 60 µs pulse width, and a .3 V amplitude shown. B) A custom neuronal spike featured stimulation 
profile with equal positive (3 V) and negative (-3 V)  amplitudes. C) An alternative neuronal spike type 





Integration of Research Tools  
 One of the primary benefits of IODA is the ability to integrate various tools used for DBS 
research directly into the system.  Figure 2.7A shows the direct acquisition of an analog joystick 
(Freedom 2.4, Logitech; Newark, CA) rotation used during a StopGo movement task.  Figure 
2.7B shows the recorded signal from a photodiode (Li-210 Photometric Sensor, Li-Cor; Lincoln, 
NE) placed on the screen during the movement task to track screen changes.   
 
Figure 2.7: Analog data signals from joystick movements and photodiode sensing screen changes during 
Stop-Signal task recorded intraoperatively during DBS procedure.  Both figures show 160 s worth of 
synced task data. A) Plot for joystick rotations either left (positive) or right (negative) for 24 trials of stop-
signal task. B) Photodiode data for 24 trials from stop-signal task with 5 trial events shown.  Baseline (top 
of figure) is start of trial, instruction cue presented to user for either left or right movement (second stage), 
joystick rotation initiated (end of second stage), stop-signal cue in 8 of 24 trials shown (fourth stage, 
lowest point), and trial end event is the return of the photodiode signal to baseline.     
Graphical User Interface 
IODA is designed to provide the user with a traditional electrophysiological view of 





typical primary view familiar to most intraoperative users.  Controls for raw signal views, filters, 
gains, motor, volume, raw data file writing, experimental tasks, and stimulating are shown.  
Additionally, IODA provides the user with individual spikes display, a dynamic range for power 
spectral analysis display, and average power view for multiple frequency bands for each 
recorded depth.  
 
Figure 2.8: Typical electrophysiological display from MER signals.  IODA display showing filtered raw 
signal on top, duration and depth of recording on top left, volume control, adjustable power spectrum, 
single spike threshold detection, probe motor control, and average power of MER signal at each recording 
step at bottom of display.   
Figure 2.9 is an alternative primary view of intraoperative electrophysiology.  Patient 
MRI files can be loaded and viewed through the GUI.  The real-time position of the MER probe 
can be superimposed on the image to provide an accurate and intuitive visualization of the 






Figure 2.9: IODA’s alternate primary electrophysiological view.  The display uses the patient’s 
preoperative MRI image and preoperative CT scan with frame to create an accurate frame-space image.  
The MER probe is superimposed onto the frame-based MRI image to show a real-time position of the 
probe as it traverses through the planned trajectory.  Audio from the filtered signal is played throughout 
the trajectory.   
Conclusions 
 
 We demonstrate a novel system that can be used intraoperatively for data acquisition and 
neural stimulation during DBS procedures.  The present system is capable of providing the 
information necessary for neurosurgeons and electrophysiologists to perform standard 
electrophysiological analysis for target localization.  In addition, the system is able to be used for 
research by combining wideband signal recording, various stimulation profiles, medical imaging, 
and experimental patient tasks.  We have developed and verified functionality of IODA in over 
75 DBS cases at our institution.   
 We found our system to provide usable and meaningful data in both the LFP and HFB 
when used for MER.  Our data analysis of both raw single unit activity and LFP activity was 
compared to recent studies and confirmed our method of acquisition and system setup to be 
correct.  We did find limitations in the signal integrity between the MER probe and pre-amplifier 
headstage.  We observed occasional points of electrical saturation in the amplifier that may have 





were able to resolve this issue by referencing the anode contact to ground and effectively record 
in a mono-polar setup.  The system amplifier unit was also found to periodically have a ground 
potential different from that of the MER ground reference.  This difference in potential for 
referenced ground inevitably caused ground loops in our system.  We resolved this by isolating 
each component in our system and referencing only the patient as the sole source for ground 
references throughout the system.  
We also observed similar stimulation effects using the integrated IODA stimulation when 
compared to the Medtronic 8840 external stimulator and the Guideline 4000.  We did find 
limitations in stimulation capabilities in our system due to variance in electrode impedance.  
However electrode impedance variability equally affected the other stimulators.  In addition, we 
observed a lower limit threshold for stimulation profiles that required shorter pulse widths than 
the ranges specified for IODA.  This is primarily due to physical hardware constraints in the 
computer and DAQ clock for µsecond pulse widths. 
We also demonstrated the capability of intraoperative DBS research using IODA.  The 
system was integrated with a joystick and photodiode sensor to sync a movement related task 
with neural recordings in the STN.  The compatibility of IODA with both sensors enabled a 
successful research experiment involving Parkinson’s patients to further understand the role of 
the STN in movement related diseases.    
IODA was tested intraoperatively with the alternative primary display.  Both 
neurosurgeons and electrophysiologists explicitly expressed the benefits of the intuitive view 
using MR images and MER audio.  Even for experienced users, the primary display for IODA 
enabled neurosurgeons to reduce surgical time, risk, and targeting error. The real-time update of 
MER probe position on patient MR images reduces the internal visualization of probe location 
usually required by neurosurgeons.     
We have successfully demonstrated a versatile and powerful intraoperative targeting 
system for nueromodulation during DBS surgeries.  This system can be used for both clinical and 
research applications during DBS cases.  The system can potentially enable neurosurgeons that 
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Background: Accurate localization of the subthalamic nucleus (STN) is critical to the success of 
deep brain stimulation (DBS) surgery for Parkinson disease.  Frame inaccuracies, imaging 
resolution, and target uncertainties can make STN DBS surgery a challenging procedure, even 
for specialty trained neurosurgeons. 
Objective: To develop a novel method for automatically identifying the location of 
microelectrode trajectories on magnetic resonance (MR) images based on the relationship 
between voxel intensities and the high frequency band (HFB) signal from microelectrode 
recordings (MER).   
Methods: We evaluated HFB power changes along 20 MER trajectories in 13 patients.  We also 
found voxel intensity values from 3-T MRI along the preoperatively planned trajectory and the 
implanted DBS lead trajectory.  We compared and scored over 100,000 potential voxel-based 
trajectories for each MER pass to identify trajectories that best matched the MER data.  Top 
scoring voxel trajectories were averaged to produce best estimates and distances to actual DBS 
leads were compared to that of planned trajectories. 
Results:  Targeting certainty was improved in over 70% of evaluated trajectories.  The averaged 
MER trajectory distance (2.33mm ± 0.2mm) was significantly closer than the planned trajectory 
distance (2.83mm ± 0.2mm) to the DBS electrode final position (P = 0.01).  In trajectories that 
initially missed the STN, subsequent trajectory adjustments were predicted with 100% accuracy 
in the direction shifted by the attending neurosurgeon. 
Conclusion: The location of DBS leads can be better estimated using this method by evaluating 





surgical procedure durations and errors associated with classic neurophysiological analysis by 







Deep brain stimulation (DBS) is a well-established surgical therapy for Parkinson’s 
disease.1  Bilateral chronic high-frequency stimulation of the subthalamic nucleus (STN) is 
typically targeted as an ideal location for alleviating the motor symptoms of Parkinson’s 
disease.2-8   Specifically, the dorsal-lateral region of the STN is traditionally targeted indirectly 
with standardized stereotactic atlases.9, 10  In recent years, direct visualization of the STN with 
magnetic resonance imaging (MRI) has been possible using a range of magnetic field strengths 
(1.5T-9.4T).   This advancement in imaging has enabled increased visibility of the STN region 
and has improved the method for preoperatively identifying an optimal target.11 
However, significant distortions of the brain do occur during DBS surgery mostly due to 
the loss of CSF and the buildup of intracranial air.12  This shifting of the brain anatomy from 
what is visualized in MR imaging creates a misalignment with the planned target for DBS. For 
multiple reasons including brain shift, microelectrode recording (MER) is often used 
intraoperatively to assist in locating the STN.13-17  With the advancement of imaging 
technologies, intraoperative signal analysis from MER has been shown to have good correlation 
to visualized structural borders, including the STN, from MR images.11, 18, 19  In addition, the 
analysis of high frequency band (HFB) signals from MER can provide quantitative information 
regarding physiological structures during DBS surgery.20, 21   
Even with MER and improved imaging resolution, DBS procedures still lack the ability 
to precisely locate the microelectrode trajectory intraoperatively in frame-based stereotactic 
coordinates.  Without having exact location coordinates of the microelectrode relative to the 
planned target, the final placement of the DBS lead could be significantly further from the target 
location than intended.  Typically the average error between the planned target and the actual 
DBS lead is 3.1 ± 1.41 mm.22    Having a more accurate location of the DBS lead prior to 
insertion can provide valuable clinical benefit by reducing the error observed between planned 
and DBS lead trajectories. 
It would be useful to provide precise locations of microelectrodes intraoperatively to 
determine if planned targets have been reached.  By providing the final trajectory position of 





We aimed to study electrophysiological signals as they relate to high resolution MR 
image voxels to provide positional information of microelectrode trajectories relative to the 
intended target.  We hypothesized that by relating the changes in HFB power recorded from 
microelectrodes to the changes in MRI voxel intensities, a calculated position of the 
microelectrode can be mapped to a MRI.  We measured the distance between the calculated 
positions of the microelectrode to the DBS lead compared to the distance between the planned 
trajectory targets to the DBS lead in order to determine if the calculated MER trajectory was 
more closely aligned to the DBS lead than the planned trajectory (Figure 3.1).  Since the DBS 
lead travels in the same trajectory as the final trajectory of the MER, we expected the calculated 
position of the microelectrode to be significantly closer to the DBS lead than the planned 
trajectory.   
 
Figure 3.1: Experimental method showing actual DBS lead trajectory, calculated MER trajectory, and 




We studied 13 consecutive patients with advanced idiopathic Parkinson disease who underwent 
STN DBS surgery at our institution (9 men, 4 women; age, 66 ± 6 years; range, 52-73 years).   
Patient selection criteria for DBS has been previously described.11  Briefly, selected patients 





medications or had levodopa-unresponsive tremor.  Patients were excluded from this study if 
contraindications to 3-T MRI scanning or abnormalities in brain anatomy existed. We performed 
the study in accordance with the policies of the Medical Institutional Review Board of the 
University of Michigan. 
 
DBS Procedure 
The DBS procedure used in this study has previously been described.11  Briefly, all patients 
underwent 3-T MRI using a coronal imaging protocol designed for visualization of the STN.  
Patients were fitted with a Leksell stereotactic frame (Elekta Instruments AB, Stockholm, 
Sweden) and underwent a preoperative 1.5-T MRI the day of surgery.  Both 3-T and 1.5T MR 
images were coregistered using a mutual-information algorithm (Analyze 9.0; AnalyzeDirect, 
Inc, Overland Park, Kansas). Frame-based bilateral surgical targeting was then performed with 
commercial software (Framelink; Medtronic, Inc, Minneapolis, Minnesota). Initial indirect 
targeting at 12 lateral, 3 posterior, and 4 inferior to the midcommissural point was performed and 
then fine-tuned to the individual patient according to the MR-visualized STN.  
During surgery, MER was performed prior to the insertion of the DBS lead for target 
localization.  Neural signals were recorded using a bipolar microelectrode (MicroTargeting 
Electrode; FHC, Bowdin, ME) advanced during surgery using a microdrive (MicroTargeting 
Controller; FHC, Bowdin, ME).  The initial position of the microelectrode was set to 15mm 
above the planned target.  The microelectrode was advanced in 0.5mm steps and held for 8 
seconds to record extracellular signals.  MER signals were amplified with a gain between 100-
1000 (D360 Isolated Patient Amplifier System; Digitimer Inc, Hertfordshire, England) and 
recorded to a computer with custom software (LabView 10.1; National Instruments, Austin, TX) 
using a USB data acquisition card (Model DT9837A; Data Translations Inc, Marlboro, MA). The 
hold time for MER recordings at each step was selected to maximize recorded HFB signals while 
minimizing overall surgical procedure duration.  Step sizes were shortened to 0.1-0.4mm when 
in the proximity of the STN. The STN dorsal and ventral borders were identified by an 
electrophysiologist.  DBS leads were placed under fluoroscopic visualization with the tip of the 
DBS lead located near the ventral border of the electrophysiological STN.  A movement 
disorders neurologist activated the DBS electrodes intraoperatively and evaluated the patient for 





resolve, a high-resolution postoperative computed tomography (CT) scan was performed to 
visualize the location of the DBS leads within the brain.  
 
MER Signal Processing  
Microelectrode recordings were filtered using a 500Hz to 2000Hz bandpass filter and 
sampled at a rate of 30kHz (LabView 10.1; National Instruments, Austin, TX).  Recordings for 
each trajectory were saved as double precision values in a computer for offline analysis.   
In order to calculate average power of the HFB based on neuronal background activity, 
large spikes recorded near the microelectrode were removed with a cutoff threshold of ±50 
microVolts.   The threshold was set based on our recoded spikes having amplitudes greater than 
± 80 microVolts.  Trajectories that had significant or sustained areas of noise were omitted from 
this analysis.   
The power spectral density was calculated over the 8-second recorded segments for each depth 
with a Fourier transform of 15000 samples per segment weighted by a hamming window.  The 
average power in the frequency domain for the HFB was analyzed for each recorded depth using 
software written in Matlab (Version 2012b; The Math Works, Inc., Natick, MA).  Each HFB 
average power value was normalized at every recorded depth to generate a normalized MER 
trajectory of average power. 
 
Image Analysis 
Details of our 3-T MR and CT imaging protocols have been previously described.11  Trajectory 
coordinates for implanted DBS lead position were identified from postoperative CT scans co-
registered to the 3-T MRI using a mutual-information algorithm (Analyze 9.0).   We used DBS 
leads with 1.5 mm contact lengths and 0.5 mm spacing between contacts (Model 3889, 
Medtronic; Minneapolis, MN).    All voxel intensities were selected from 3-T MR images with a 
voxel resolution of (0.5mm × 0.5mm × 0.5mm).  Voxel intensity values were inversed to 
represent physiological structures and normalized for each trajectory.  Low intensity values on 
our MR protocol represent darker, denser structures; however electrophysiological analysis has 
higher power values in more dense structures.19, 21  Therefore, for each voxel intensity trajectory, 






Selection of Potential Voxel-Based Trajectories  
Potential voxel trajectories were selected by creating a search window between two cubes (8 
voxels × 8 voxels × 8 voxels), with one cube centered on the entry coordinate and the other cube 
centered on the target coordinate of the planned trajectory.  Potential trajectories were created by 
varying entry coordinates in the search cube, varying target coordinates in search cube, or both.   
Potential trajectory selection criteria included only trajectories of the same length as that of the 
MER trajectory and trajectories that were within a ± 3 degree range for both the ring and arc 
angles of the planned trajectory.  For an average MER trajectory of length 20mm this method 
resulted in over 100,000 potential trajectories within 8 voxels of the planned trajectory.  Each 
potential trajectory had entry and exit coordinate recorded as well as the inversed normalized 
voxel intensities along its trajectory at every recorded depth.  Figure 3.2A shows an example of 
this selection method using three potential voxel-based trajectories and the respective inverse 
voxel intensity plots.   Figure 3.2B visualizes the search window and potential voxel trajectories 
on the coronal view of a targeted STN.   
 
Figure 3.2: A) Potential trajectories and the associated intensities along each track through thalamus, 
subthalamic nucleus, and substantia nigra (SN) shown.  B) 3-T MRI coronal view of STN targeted 
potential voxel trajectories in an 8 voxel search window.  110,000 trajectories shown with score indicated 
by color (Red = high score, Green = low score).  The black line is the average Top 7% of active 





Scoring Each Potential Voxel Intensity Trajectory to HFB Power Trajectory 
The scoring method used voxel based MER trajectory estimates to compare voxel intensities to 
the observed HFB power data from the MER trajectory.  The best voxel trajectory estimate was 
based on the average of the top scoring voxel trajectories in rank order.  Scores were determined 
by using the sum of absolute errors at every recorded step between each voxel trajectory and the 
recorded HFB MER trajectory.   
A score from 0 to 1 was assigned for each normalized voxel trajectory compared to the 
normalized HFB power trajectory.  Potential voxel trajectories that were well aligned with the 
HFB power trajectory had small deviations at every recorded depth and therefore had high 
scores.  Potential voxel trajectories with large deviations from the HFB power trajectory had 
relatively lower scores.  Figure 3.3 shows the distribution of scores for potential voxel 
trajectories of an individual MER trajectory analysis.   After all potential trajectories were 
scored, the results were sorted based on score and the top 7% of trajectories were averaged for a 
representative average trajectory estimate.  A regression analysis was used across all sorted 
trajectory data to identify the percentile that best minimized the distance between the average 
trajectory and the final electrode position. 
 
Figure 3.3: Distribution of potential voxel trajectory scores for an individual MER track.  The top 7% of 
trajectories (scores ≥ 0.886) marked with grey vertical line. 
Validation of Scoring Method  
To validate our scoring method we tested for accuracy in both scoring and location of the 
analyzed potential voxel trajectories.  We first selected a test trajectory and found the voxel 







































































compared to the test using the test trajectory’s voxel intensities instead of HFB power data from 
MER.  This ensured that the voxels of the test trajectory were within our search window.  As 
expected, the scoring method successfully identified the test trajectory among the potential voxel 
trajectories in the search window as the top scoring trajectory (score = 1) with 0 mm calculated 
deviation from the test trajectory.  We had the same results when repeated in all MR images used 
for this study.  Figure 3.4 shows the results of this first simulation, labeled ‘No Shift’. 
We additionally tested for accuracy in location by intentionally shifting the test trajectory 
and comparing the resulting potential trajectory scores and locations to this shifted test trajectory.  
We first intentionally shifted the test trajectory by 1.02 mm (2 voxels) and found the associated 
voxel intensities that defined this vector.  We scored potential trajectories in the same search 
window as the first test but used the shifted-test voxel intensities instead of the test intensities.  
The scoring method correctly found the shifted trajectory within the potential voxel trajectories 
at a deviation from the original test trajectory of 1.02 mm.  The results were consistent across all 
the MR images in our study.  We repeated this test using a shift of 1.4mm and found the method 
to correctly locate the shifted trajectory 1.4mm away from the original test.  Figure 3.4 displays 
these tests between intended shift and calculated shift.    
 
Figure 3.4: Scoring Method Simulation: Intentional shifts of 0mm, 1.02mm, 1.4mm from original test 
trajectory against the calculated shifts from the scoring method.  In all cases (N = 13 patient MR images), 
the calculated shifts were equal to the intended shifts for each shift test. 
Statistical Analysis 
Statistical analysis was performed with commercially available software (Matlab 2012b; 
The Math Works, Inc., Natick, MA, Excel; Microsoft Inc, Redmond, WA).  Paired two tailed t-
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to planned trajectory distances.  Distances between the DBS electrode trajectory, planned 
trajectory, and averaged calculated trajectory were calculated at the Z coordinate of the planned 
target.  Distances in millimeters represent the two dimensional distance of the X and Y 
coordinates at the planned Z coordinate for every trajectory.  Results are reported as mean ± 
SEM unless otherwise noted.   
Results 
 
A total of 20 STN targeted trajectories from 13 PD patients were available for analysis.  
Of these, 14 trajectories were final trajectories representing the final trajectory of the DBS 
electrode.  Four of the available trajectories represented a first pass MER trajectory with the 
subsequent pass moved from the initial position and considered the final trajectory.  Two 
trajectories from two patients were omitted due to DBS lead position change after intra-operative 
testing yielded poor symptom control.  
The average deviations from the DBS lead for the planned and automatically calculated 
trajectories on a typical STN targeted trajectory were compared for significance.  The distance 
between the averaged top 7% calculated trajectories and the DBS lead was 2.33 ± 0.2mm. The 
distance between the plan trajectory and the DBS lead was 2.83 ± 0.2mm.  A paired t-test 
revealed that the calculated trajectories were significantly closer to the DBS lead than the 
planned trajectories for each patient trajectory (P = .01). 
Figure 3.5 shows a significant correlation between the calculated deviations of the 
estimated MER trajectory and the measured deviation of the planned trajectory to the DBS lead 
(R= .58, P = .02).  Of the final 14 trajectories, 10 showed a significant reduction in distance from 
the actual DBS lead position and 2 trajectories had no significant difference compared to the 






Figure 3.5: Correlation of Planned trajectory and Estimated MER trajectory distances from actual DBS 
lead.  A majority of calculated trajectories were closer to the actual lead position than were planned. 
Figure 3.6 shows the distances in the X and Y direction of the top 7% average and plan 
trajectories to the DBS lead.  The Y-coordinate of the top 7% trajectories (Y = .80 ± .50 mm) 
was significantly closer to the DBS lead than the plan trajectory (Y = 1.52 ± .50 mm, P < .001).  
There was a trend in the X-coordinate of the top 7% trajectories (X = .43 ± .35 mm) to be closer 
to the DBS lead than the plan trajectory (X = .62 ± .42 mm, P = .19).    
 
Figure 3.6: Distances from DBS lead in X and Y direction for calculated and plan trajectories compared 
to show significant reduction in calculated trajectory distance.  The Y-coordinate of the calculated 
trajectory was significantly smaller than the Y-coordinate of the plan trajectory. 
We also evaluated the four first pass MER tracks with our scoring method to determine if 
the direction and magnitude of adjustment of the subsequent final trajectory could be predicted.  
The average adjustment made by the neurosurgeon after each of these tracks was 2 ± 0 mm 











































but with a smaller magnitude than that of the neurosurgeon, 0.46 ± 0.1 mm in the anterior 
direction.  
Discussion 
The effectiveness of STN DBS surgery for Parkinson’s disease is dependent on the 
accuracy of targeting the STN.  Targeting the STN traditionally involves using an imaging 
method to define an initial target estimate and then using intraoperative MER and clinical testing 
to optimally reposition the electrode.  The advancement of imaging technologies has enabled 
direct visualization of the STN and has accounted for improved targeting methods.11, 19  
However, during surgery the brain shifts and preoperatively planned targets are also shifted.  To 
account for this, subjective and quantitative analysis of HFB signals from MER enable trained 
neurosurgeons to determine the location of the microelectrode.20, 21, 23 
In this study, we used 3-T MRI voxel intensities and quantitative analysis of the HFB 
signal obtained during DBS surgery to better estimate the location of the microelectrode 
trajectory for patients with Parkinson Disease.  These results demonstrated that the calculated 
MER trajectory was significantly closer to the DBS lead than the planned trajectory was to the 
DBS lead.  In this study, one limitation to our measure of accuracy was the surgical uncertainties 
of final lead placement. The distance between the calculated and actual trajectories was primarily 
caused by deviations of the DBS lead after insertion through the guiding cannula.  Although the 
cannula provides a rigid path for the DBS lead to travel, there are typically slight deviations 
between the end of the cannula and target depth.   
A basic scoring method was used to evaluate potential voxel trajectories compared to the 
HFB power signal recorded from MER.  This method was validated to ensure accurate scores 
and locations were assigned to each potential voxel trajectory.  We found this method to be 
robust and efficient when tested with known trajectory locations.  In every test of fixed and 
variable trajectory locations, the scoring method correctly identified the known trajectory out of 
the over 100,000 potential trajectories analyzed.  For our study, we chose a large enough search 
window to account for the observed error between the planned target and the DBS lead (2.83 ± 
0.2 mm).  We confined our search space for potential trajectories to approximately 4 mm.  This 
may have limited our study from verifying our results with larger search windows.   
Interestingly, of the available MER trajectories for analysis in our study, four were 





electrophysiological confirmation of the STN and thus required a subsequent MER track in an 
alternative location.  The automated method provided the information necessary to determine the 
direction to shift the subsequent MER trajectory, i.e. a shift anterior, posterior, medial, or lateral 
of the planned target.  However, due to the limited resolution (2 mm shifts) and direction of 
adjustment in our surgical setup we were unable to draw any significant results regarding the 
magnitude of shift necessary to reach the intended target. 
This method could potentially be used to automate and visualize the MER process while 
possibly reducing surgical time, risk, and error.  It may also enable neurosurgeons that are not 
specially trained to perform DBS procedures by automating the analysis of MER and targeting.  
Although our study data suggests that calculating the position of a microelectrode with HFB and 
image analysis may be performed automatically without the need to analyze either, this method 
cannot completely replace intraoperative electrophysiological monitoring given that 




With the advancements in MRI technology and the quantitative analysis of HFB 
electrophysiology signals, we show a new method for locating and visualizing a microelectrode 
intraoperatively.  We used 3-T MRI voxel intensities and quantitative analysis of the HFB signal 
from MER to better estimate the locations of microelectrode trajectories for patients with 
Parkinson’s disease.  These results demonstrated that the calculated position of the MER 
trajectory was significantly closer to the DBS lead than the planned trajectory was to the DBS 
lead.  These results indicate that this method may provide significant improvement to DBS lead 
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Chapter 4 : Subthalamic Beta Activity and Optimal Deep Brain Stimulation 
Sites Spatially Dependent 
Abstract 
 
Objective:  Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an effective 
therapy for Parkinson’s disease (PD).  However, optimal stimulation sites of the STN region are 
frequently contested.   The aim of this study was to corroborate results from conflicting studies 
by providing evidence that the relationship between sites of beta hypersychrony and optimal 
stimulation are spatially dependent relative to the STN region. 
Method: We measured local field potential (LFP) activity in the beta band from 26 subthalamic 
regions in 13 patients undergoing DBS treatment for PD.  We recorded beta LFP data from 
microelectrodes between 2 mm above the electrophysiological STN to the ventral border and 
assessed the peak power in the beta band from each recording.  3-T magnetic resonance imaging 
(MRI) was used to identify the midpoint of the STN.  We used postoperative MRI to locate each 
trajectory relative to the midpoint and the location of the independently chosen contact for 
chronic stimulation.  
Results:  Trajectories categorized as medial to the STN midpoint had locations of peak beta 
power correlated with optimal sites of stimulation.  Conversely, trajectories categorized as lateral 
had locations of peak beta power significantly below optimal contact sites.  The optimal contact 
sites correlated with the dorsal border of the STN in both medial and lateral trajectories.   
Interpretation:  These results suggest that there is a dependence on location within the STN 
when using areas of peak beta activity to determine sites of optimal stimulation for DBS in PD 
patients.  These results may have further implications in studies modeling STN beta oscillations, 







Deep brain stimulation (DBS) is a well-established surgical therapy for Parkinson’s 
disease.1  Bilateral chronic high-frequency stimulation of the subthalamic nucleus (STN) 
alleviates the motor symptoms of Parkinson’s disease.2-8  However, within the STN region there 
is little consensus as to the most optimal site for chronic stimulation by the active contact of the 
implanted DBS lead. 
Recent studies have presented evidence suggesting excessive synchronization of the beta 
frequency band (13-30Hz) in the basal ganglia in patients with Parkinson’s disease.9-12  
Additionally, it has been shown that the peak power of the beta signal occurs in the sensorimotor 
region of the STN, generally observed as the dorsal region of the STN.9, 13-17   Increasing 
evidence points to locations of peak beta activity as the most optimal sites for stimulation in the 
STN region.18-22  Conversely, it was reported that sites of peak beta power are more centrally 
located within the STN and therefore may be a poor indicator for optimal stimulation sites.23  
Independent of locations of peak beta hypersynchrony, others have reported the dorsal border of 
the STN (DB-STN) to be the most optimal location for chronic stimulation based on 
postoperative clinical effect.24, 25  However, there are significant methodological differences in 
many of these studies ranging from variations in local field potential (LFP) recordings, poor 
spatial resolution during signal recording, and low imaging resolution for confirmation of 
trajectory location. 
Typically, microelectrode recordings (MER) are used intraoperatively to assist in locating 
the electrophysiological STN.26-30  Signals recorded through microelectrodes range in frequency 
and enable neurosurgeons to use electrophysiological methods to identify signature neuronal and 
local field potential (LFP) activity near the STN.31 In this study, the STN borders were 
electrophysiologically identified using MER.  Beta LFP signals were recorded using the 
microelectrode from 2mm above the DB-STN to the ventral border of the STN in 0.1 to 0.4 mm 
increments.  By recording LFPs with microelectrodes, spatial resolution is significantly 






In recent years, improved targeting has been possible through direct visualization of the 
STN with advancements in magnetic resonance (MR) imaging (MRI).32-34  Direct visualization 
of the STN has also enabled increased spatial resolution for analysis between trajectory locations 
and target sites within the STN.9, 13-17  Previous studies relating beta power to optimal stimulation 
sites have lacked the resolution necessary to precisely locate beta trajectories relative to the STN.  
Although beta power has been shown to vary dorso-ventrally in the STN, it is still unclear 
whether there is a significant difference in beta power profiles medio-laterally and antero-
posteriorly in the STN region.  
We hypothesize that the discrepancies seen in recent findings between peak beta power 
sites and optimal simulation locations can be explained by differences in LFP recorded trajectory 
locations relative to the STN midpoint using high resolution MR imaging.  In this study, we first 
demonstrated our LFP recording method by showing similar beta power trends as those observed 
in comparable studies.  We then categorized each LFP trajectory based on its relative location to 
the midpoint of the visualized STN to show how contested claims regarding beta and optimal 




We studied 13 consecutive patients with advanced idiopathic Parkinson disease who 
underwent STN DBS surgery at our institution (9 men, 4 women; age, 66 ± 6 years; range, 52-73 
years).   Patient selection criteria for DBS has been previously described in Patil et al.33  Briefly, 
selected patients were diagnosed with Parkinson disease and had motor fluctuations not well 
controlled by medications or had levodopa-unresponsive tremor.  Patients were excluded from 
this study if contraindications to 3-T MRI scanning or abnormalities in brain anatomy existed. 
We performed the study in accordance with the policies of the Medical Institutional Review 
Board of the University of Michigan. 
 
DBS Procedure 
The DBS procedure used in this study has previously been described.33  Briefly, all 





STN.  Patients were fitted with a Leksell stereotactic frame (Elekta Instruments AB, Stockholm, 
Sweden) and underwent a preoperative 1.5-T MRI the day of surgery.  Both 3-T and 1.5T MR 
images were coregistered using a mutual-information algorithm (Analyze 9.0; AnalyzeDirect, 
Inc, Overland Park, Kansas). Frame-based bilateral surgical targeting was then performed with 
commercial software (Framelink; Medtronic, Inc, Minneapolis, Minnesota). Initial indirect 
targeting at 12 lateral, 3 posterior, and 4 inferior to the midcommissural point was performed and 
then fine-tuned to the individual patient according to the MRI-visualized STN.  
During surgery, MER was performed prior to the insertion of the DBS lead for target 
localization.  Neural signals were recorded using a bipolar microelectrode (MicroTargeting 
Electrode; FHC, Bowdin, ME) advanced during surgery using a microdrive (MicroTargeting 
Controller; FHC, Bowdin, ME).  The initial position of the microelectrode was set to 15mm 
above the planned target.  The microelectrode was advanced in 0.5mm steps and held for 8 
seconds to record extracellular signals and local field potential signals.  MER signals were 
amplified with a gain between 100-1000 (D360 Isolated Patient Amplifier System; Digitimer 
Inc, Hertfordshire, England) and recorded to a computer with custom software (LabView 10.1; 
National Instruments, Austin, TX) using a USB data acquisition card (Model DT9837A; Data 
Translations Inc, Marlboro, MA). The hold time for MER recordings at each step was selected to 
maximize recorded HFB and LFP signals while minimizing overall surgical procedure duration.  
Step sizes were shortened to 0.1-0.4mm when in the proximity of the STN. The STN dorsal and 
ventral borders were identified by an electrophysiologist.  DBS leads were placed under 
fluoroscopic visualization with the tip of the DBS lead located near the ventral border of the 
electrophysiological STN.  A movement disorders neurologist activated the DBS electrodes 
intraoperatively and evaluated the patient for symptom improvements and side effects. After 
several weeks, allowing intracranial air to resolve, a high-resolution postoperative computed 
tomography (CT) scan was performed to visualize the location of the DBS leads within the brain.  
 
Local Field Potential Processing 
Microelectrode LFP recordings from 2mm above the DB-STN to the ventral border were 
bandpass filtered between 1Hz to 250Hz and downsampled to a sampling frequency of 500 Hz. 





step was calculated by averaging the sum of the squared amplitudes of the Fast Fourier 
Transform (FFT) at each recording step (Matlab 2012b; The Math Works, Inc., Natick, MA).  
The FFT included only the first 8 seconds of recorded beta LFP with the first second omitted 
from analysis to prevent motor noise from the microdrive corrupting the analysis.  Histograms 
were created using each recorded depth average power and a curve was fitted to the resulting plot 
for figures.  Noise from the microdrive or other periods of high electrical noise artifacts observed 
in the recorded LFP signal were removed from analysis.  In this study, we observed noise 
artifacts to be greater than 3mV and therefore selected this as our threshold for noise detection.  
Recording depths were normalized to the top of the electrophysiological STN in each trajectory, 
where 0 mm was the DB-STN.  Beta power and contact sites were referenced as a distance away 
from the DB-STN, 0 mm.  The dorsal region was considered to be 0 - 50% of the traversed STN 
in each trajectory.  The ventral region of the STN was considered to be 51-100%.  
Image Analysis 
Details of the 3-T MR and CT imaging protocols used in this study are described in Patil 
et al.33  Briefly, trajectory coordinates for DBS lead locations were identified from postoperative 
CT scans coregistered to 3-T MRI using a mutual-information algorithm (Analyze 9.0).  Spatial 
locations of active contacts on DBS leads were calculated from the midpoint of the distal most 
contact (Contact 0) on the visualized DBS lead from coregistered CT images.  We used DBS 
leads with 1.5 mm contact lengths and 0.5 mm spacing between contacts (Model 3889, 
Medtronic; Minneapolis, MN).  The active contact for each trajectory was recorded for each 
patient during a 6-month postoperative programming session.  The optimal contact was selected 
independent of DB-STN location or peak beta location and was based on clinical benefit 
evaluated by a neurologist.   
The dimensions of the STN (anterior-posterior, medial-lateral) used for midpoint analysis 
were measured from coronal slices.  Figure 4.1 illustrates the method used in this study to 
identify the midpoint, using a theoretical model of the STN. The most anterior and posterior 
points of the visualized STN were averaged to determine the midpoint of the STN to define 
medial and lateral regions.  The most medial and lateral points of the visualized STN were used 
to find the midpoint of the STN defining the anterior and posterior regions.  Trajectories were 





study, all but four trajectories were categorized as posterior to the STN midpoint. These four 
trajectories were not included in the analysis of medial and lateral trajectories.       
 
Figure 4.1: STN midpoint analysis on a three dimensional STN model.  The anterior and posterior poles 
are shown through an angled coronal view.  Perpendicular planes are drawn through the midpoint to 
illustrate the sagittal and coronal axes.  
Statistical Analysis 
Statistical analysis was performed with commercially available software (Matlab 2012b; 
The Math Works, Inc., Natick, MA, Excel; Microsoft Inc, Redmond, Washington).  Distances 
between optimal contact, peak beta power, DB-STN, and VB-STN are reported in millimeters. 
Results are expressed as mean ± SD unless otherwise noted.  To compare strength of linear 
dependence between peak beta power and optimal contact sites, we used the Pearson product-
moment correlation coefficient R.  Significance was calculated with a significance level of .05 
using paired two tailed t-tests.  
Results 
 
A total of 26 STN targeted trajectories with recorded LFP signals from 13 PD patients 
were available for analysis.  Of these, 19 trajectories had usable beta LFP signals from which 
391 beta power sites were analyzed.  Four trajectories were excluded for being categorized as 





artifacts throughout the recorded LFP signal due to technical complications within the surgical 
setup during MER.   
The mean dorsoventral length of recorded STN was 4.0 ± 0.58 mm.  There was not a 
significant difference between the electrophysiologically defined length of the STN and the MRI 
visualized length of the STN (4.30 ± 1.13 mm, P = .38).  There also was not a significant 
difference in the location of the DB-STN relative to the planned target for the 
electrophysiologically defined STN (13.90 ± 1.20 mm) and the visualized DB-STN (13.97 ± 2.7 
mm, P = .93). 
Beta LFP Peak Power Location Varies Dorsoventrally Through STN 
Figure 4.2 displays varying locations of peak beta power with respect to the STN in two 
sample trajectory recordings.  Figure 4.2A shows the peak beta power occurring before the 
dorsal border of the STN, similar to recent studies.13, 19, 20, 22  Conversely, Figure 4.2B shows the 
peak beta power occurring more centrally within the STN, also similar to previous results.23  Of 
the available beta LFP trajectories in this study, 79% had beta peaks in or above the dorsal region 
of the STN (1.06 ± 0.69 mm).  Of these trajectories, 42% had beta peaks above the DB-STN 
(0.89 ± 0.67 mm).  There was a significant correlation between beta peak locations and the DB-
STN, R = .47, P = .03 as illustrated in Figure 4.3A.  
 
Figure 4.2: Trajectories of beta power through the STN.  STN dorsal and ventral boundaries marked with 
dotted lines. A) Individual beta power trajectory with normalized peak beta power (13.0 mm) occurring 
before the DB-STN (14.5 mm). B) Individual beta power trajectory with normalized peak beta power 
(14.4 mm) occurring within marked STN (13 mm – 17mm). 





Optimal contact locations varied minimally along the dorsoventral length of the STN from 2mm 
dorsal to the DB-STN to within the dorsal region of the STN.  Of the available trajectories, 63% 
of trajectories had optimal contacts within or above the dorsal region of the STN (1.0 ± 0.74 
mm), with 42% of active optimal contacts above the DB-STN (0.98 ± 0.86 mm).  Figure 4.3B 
shows a significant correlation between optimal contact location and the DB-STN, R = .42, P = 
.05.  There was a weaker correlation between peak beta locations and optimal contact sites as 
seen in Figure 4.3C, R = .37, P = .08.  
 
Figure 4.3: Correlation plots for optimal contact locations, peak beta power sites, and the DB-STN for all 
recorded trajectories.  Beta trajectories ranged between 11 mm to 19mm of total recorded track (0 mm to 
21mm)  A) The correlation between the DB-STN and the peak beta site within each trajectory. B) The 
correlation between optimal contact site and the DB-STN for all beta trajectories. C) The correlation 
between all contact sites and peak beta locations. 
Variations in Peak Beta and Optimal Contact Sites Explained by Trajectory Location Relative to 
Visualized STN Midpoint  
Figure 4.4 displays the representative average trajectories in this study conditioned on 
locations relative to STN midpoints.  47% of trajectories were recorded medial of the STN 
midpoint, while 53% were lateral.    
Within the medial trajectory group, the optimal contact location was only slightly below 
but not significantly different from the peak beta power site (-0.36 ± 1.6 mm, P = .57).   The 
optimal contact site was also slightly below but not significantly different from the DB-STN (-
0.4 ± 0.94 mm, P = .30).  The peak beta power location was not significantly different from the 
DB-STN (-0.04 ± 1.6 mm, P = .95). 
Within the lateral trajectory group, the optimal contact site was significantly above the peak beta 





STN (-1.51 ± 1.48 mm, P = .012).  The DB-STN was not significantly different from the optimal 
contact site (0.35 ± 1.43 mm, P = .51).  In all observed trajectories, the optimal contact locations 
and all but one peak beta sites were above the visualized STN midpoint.   
 
Figure 4.4: Averaged group for medial and lateral trajectories through the STN.  A coronal projection of 
the left STN is shown with black horizontal bars marking the DB-STN and VB-STN for each trajectory.  
The STN midpoint is centered at (0,0).  Illustrated contacts of DBS lead are shown in grey with the 
optimal contact for stimulation in red.  The sites of average peak beta power are shown as blue diamonds 
along each trajectory. 
Discussion 
 
In this study, we examined the relationship between the optimal contacts used in DBS for 
the treatment of Parkinson’s disease with the location of peak beta power recorded during MER.  
We recorded LFP activity from microelectrodes targeted for the STN and visualized the STN 
midpoint using high resolution MR imaging (3T).  We determined whether the location of peak 
beta power is correlated to the site of optimal stimulation.  These results suggest that the optimal 





are medial of the STN midpoint. There was no significant difference between the locations of 
peak beta power, DB-STN, and optimal contacts for medial trajectories.  The optimal contact and 
peak beta sites were at or near the DB-STN for medial trajectories.  However, in trajectories that 
were lateral of the STN midpoint, the peak beta location was significantly below the active 
contact and DB-STN.  There was no significant difference between the optimal contact site and 
the DB-STN for lateral trajectories. 
The optimal location for stimulation from DBS leads has been a highly debated.  Recent 
studies have found the most optimal location for stimulation to be at or above the DB-STN.18, 24, 
25  While other studies have claimed the optimal location for stimulation is associated with the 
location of peak beta power.13, 19, 20, 22  Additionally, peak beta power has been shown to occur in 
the sensorimotor region of the STN, generally observed as the dorsal region of the STN.9, 13-17  
However, Solages et al found that peak beta power occurred more central in the STN.23   
We applied similar methods of analysis, as in related studies, to the beta-band of LFP 
signals recorded during MER for each trajectory.  Initially, we found that overall beta correlated 
well with the DB-STN but less so with the optimal contact location.  A closer inspection of each 
trajectory revealed similar results to the differing observations of that found by Zaidel et al and 
Sloages et al.13, 23 Some trajectories in our study had sites of peak beta power dorsal to the DB-
STN, whereas others had peak beta sites within the central region of the STN.  The optimal 
contact location did not vary much from the DB-STN region.  In order to determine if spatial 
location relative to the STN affected optimal contact sites we categorized each trajectory based 
on its location relative to the visualized STN midpoint.  Unlike previously reported studies, we 
used high resolution MR imaging (3T) to directly visualize the STN to identify the STN 
midpoint and locate each LFP trajectory relative to the visualized midpoint. 
We found a fairly equal distribution of trajectories that were medial and lateral of the 
STN midpoint in the posterior region.  Trajectories that were more medial of the STN midpoint 
had beta peaks and optimal contacts near the DB-STN.  This category of trajectories confirms 
previous findings of optimal contact sites correlated with peak beta hypersychrony as well as the 
DB-STN.24  Conversely, trajectories that were more lateral of the STN midpoint had peak beta 
sites significantly ventral of the optimal contact site and DB-STN.  There was no significant 





average, we did confirm peak beta power locations to be in the dorsal region of the STN.  
However, sites of optimal contact were significantly more dorsal to these peak beta locations.  
This result may be limited by our selection of the midpoint of the optimal contact to calculate 
significance.  In our study, DBS lead contacts were 1.5mm in length and selection of a point in 
the contact closer to peak beta hypersychrony may provide improved correlations.  However, 
unlike previous studies, we had significantly better resolution during MER recordings and 
therefore were more precise with the location of peak beta relative to the optimal contact.  It 
should be noted, on average the active contact was either the nearest point of stimulation or the 
contact just dorsal to the peak beta point for lateral trajectories.   
Interestingly, we found optimal contacts to be significantly ventral of peak beta sites for 
the four trajectories excluded from our analysis for being anterior of the STN midpoint (-2.27 ± 
1.39 mm, P = .02).  We observed no significant difference between the peak beta site and the 
DB-STN of these lateral-anterior trajectories (-0.3 ± 1.1 mm, P = .33).  This result may be 
explained by the dorsal lateral posterior region of the STN being the most therapeutically 
beneficial site for DBS stimulation.  The optimal contact of these anterior trajectories was the 
closest contact to the lateral posterior region of the STN.  
We present a potential explanation for the differences in recently published results 
indicating optimal contact locations for STN DBS by precisely locating recorded trajectories 
relative to the STN using high resolution MRI. By direct visualization of the STN we were able 
to determine the location of each of our MER LFP trajectories relative to the individually 
visualized STN midpoints.  We have shown that differences in optimal contact and peak beta 
locations may be dependent on the relative location of the recorded trajectory to the STN 
midpoint.  Beta oscillatory activity may vary significantly depending on region of STN 
traversed.  We found that trajectories medial of the STN midpoint had optimal contacts that were 
significantly correlated to the beta-LFP peak power location and the DB-STN.  We found 
trajectories lateral of the STN midpoint to have optimal contacts that were significantly 
correlated with the DB-STN but not with peak beta power sites; which were significantly ventral 
of the DB-STN.  These results may have further implications in studies modeling STN beta 
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Chapter 5 : Activation of Subthalamic Nucleus in Local Field Potentials and 
Single Units during Response Inhibition 
Abstract 
 
Background: Activation of the subthalamic nucleus (STN) during response inhibition is 
important for understanding basal ganglia circuitry and motor decision connections in the brain. 
Objectives: The goal of this study was to record local field potential (LFP) and single unit 
activity (SUA) from the STN intraoperatively during a stop-signal task.  We analyzed the 
activation of the theta, alpha, and beta bands of the LFP and the firing frequency modulations of 
single units in order to confirm previously reported results of STN activation during response 
inhibition. 
Methods: We collected LFP and SUA from wideband recordings using microelectrodes in the 
STN of 3 patients undergoing deep brain stimulation (DBS) surgery for Parkinson’s disease.  
Patients completed a stop-signal task while a microelectrode was held in a fixed location within 
the STN.  The task was analyzed on triggers for movement cue, movement onset, and the stop-
signal cue.  We compared STN activation in trials for successful and unsuccessful movement 
inhibition and trials without stop-signals. 
Results:  We found significant increases in the theta and alpha bands in the presence of the stop-
signal and movement onset (P = .002, P < .001, P = .002).  We observed decreases in beta power 
for unsuccessful response inhibition compared to successful inhibition.  SUA also showed 
decreases in firing frequency on the stop signal for failed inhibition versus success.  Generally 
we observed single units to be movement responsive indicating recording locations to be in the 
sensorimotor region of the STN. 
Conclusion:  We confirm recent studies reporting variations in the theta, alpha, and beta bands 





difference seen in beta power of the STN between failed and successful response inhibition.  
These results provide further evidence that the STN is considered the “brake” for planned actions 







Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an effective treatment for the 
motor symptoms of Parkinson disease (PD).  The STN is considered to plays a major role in 
motor control by influencing the basal ganglia through inhibitory signals.1  Specifically, the STN 
is thought to regulate the inhibition of planned and initiated movements.   
Recent studies using functional magnetic resonance imaging (fMRI) reported increased 
BOLD signal response in the STN during movement inhibition for patients performing a stop-
signal task.2-6  The stop-signal task was designed to isolate and assess the neural network 
responsible for sudden cancellation of an intended or in-progress action.7  Although many 
variations exist, the paradigm generally prompts subjects to respond in the direction of an on-
screen cue either through a button press or rotation of a joystick.  Intermittently throughout the 
task, a stop cue is presented and the subject is instructed to refrain from response.  The stop 
signal is varied to prevent subjects from anticipating the cue and is typically designed to elicit 
successful response inhibition in half of all stop-signal trials.   
Studies using the stop-signal task and recordings from within the STN have also shown 
significant activation of the STN during movement inhibition in local field potentials (LFP).1, 6  
The power of the LFP beta band was observed to significantly decrease prior to and during 
movement.  Beta power has also been reported to reduce significantly with dopamine 
replacement medication and DBS.8-13  The theta band has also been reported to show significant 
increases during inhibition signals in stop-signal tasks.6 
Here we investigate the implication of the beta, theta and alpha bands in the LFP as well 
as single units in the inhibitory role of the STN.  We intraoperatively recorded LFPs and SUA 
from within the STN of PD patients during a stop-signal task using microelectrode recording 
(MER) probes.  We confirmed previously reported findings of distinct patterns of STN activity 
in different LFP frequency bands associated with successful and unsuccessful inhibition to 
movement.  We also observed movement responsive units providing evidence of task recordings 









We studied 3 consecutive patients with advanced idiopathic Parkinson disease who 
underwent STN DBS surgery at our institution (3 men; age, 66 ± 6 years; range, 52-73 years).   
Patient selection criteria for DBS has been previously described in Patil et al.14    Briefly, 
selected patients were diagnosed with Parkinson disease and had motor fluctuations not well 
controlled by medications or had levodopa-unresponsive tremor.  Patients were excluded from 
this study if abnormalities in brain anatomy existed or intraoperative fatigue prevented 
completion of the task. Patients were introduced to the stop-signal task two weeks prior to 
surgery in a preoperative clinical visit.  In this study, only intraoperative off-medication patient 
data is presented.  We performed the study in accordance with the policies of the Medical 
Institutional Review Board of the University of Michigan. 
 
DBS Procedure 
The DBS procedure used in this study has previously been described.14   Briefly, all 
patients underwent 3-T MRI using a coronal imaging protocol designed for visualization of the 
STN.  Patients were fitted with a Leksell stereotactic frame (Elekta Instruments AB, Stockholm, 
Sweden) and underwent a preoperative 1.5-T MRI the day of surgery.  Both 3-T and 1.5T MR 
images were coregistered using a mutual-information algorithm (Analyze 9.0; AnalyzeDirect, 
Inc, Overland Park, Kansas). Frame-based bilateral surgical targeting was then performed with 
commercial software (Framelink; Medtronic, Inc, Minneapolis, Minnesota). Initial indirect 
targeting at 12 lateral, 3 posterior, and 4 inferior to the midcommissural point was performed and 
then fine-tuned to the individual patient according to the MRI-visualized STN.  
During surgery, MER was performed prior to the insertion of the DBS lead for target 
localization.  Neural signals were recorded using a bipolar microelectrode (MicroTargeting 
Electrode; FHC, Bowdin, ME) advanced during surgery using a microdrive (MicroTargeting 
Controller; FHC, Bowdin, ME).  The STN dorsal and ventral borders were identified by an 
electrophysiologist.  Once the MER probe was confirmed within the STN region a location with 





DBS leads were placed under fluoroscopic visualization with the tip of the DBS lead 
located near the ventral border of the electrophysiological STN.  A movement disorders 
neurologist activated the DBS electrodes intraoperatively and evaluated the patient for symptom 
improvements and side effects. After several weeks, allowing intracranial air to resolve, a high-
resolution postoperative computed tomography (CT) scan was performed to visualize the 
location of the DBS leads within the brain.  
 
Stop Signal Paradigm 
 The stop signal task was used to assess motor inhibition response in PD patients during 
DBS surgery.7  The task used in this study is an adaptation of that described in Aron et.al.2  
Briefly, the stop-signal task enables the examination of neural structures involved in going and 
stopping motor movement decisions.  The paradigm presented patients with choice responses 
and occasionally presented a stop signal to make patients attempt to inhibit their response.  The 
task was optimized to maximize differences in recorded signals between Stop and Go events by 
predetermining the sequence of Go and Stop trials.  Stop trials were triggered with a Stop-signal 
delay (SSD); which was dynamically adjusted to yield a 50% successful inhibition rate so that 
Stop-signal-Reaction-Time (SSRT) could be estimated for each session.  The SSRT was 
calculated by subtracting the SSD from the median reaction time of Go trials.     
Specifically for this study, the stop-signal task was presented to patients intraoperatively 
on a computer display.  Patients were given a joystick (Freedom 2.4, Logitech; Round Rock, TX) 
and instructed to rotate the joystick with the contralateral hand in the direction of the Instruction 
cue presented on screen.  Patients completed at least 4 blocks of trials for each session, with each 
block consisting of 24 trials of both Go and Stop trials.  Each trial in the task started with a Trial 
Begin cue on a black screen which lasted for 1 second and was followed by the Instruction cue.  
In this study, Instruction cues were presented as white blocks filling half the screen; indicating 
direction of rotation while the other half of the screen remained black.  Stop signals were flashed 
in red over white blocks in Stop trials.  Trial durations were set to 2 seconds from Trial Begin to 
Trial End.  If the patient completed a Go trial by a full rotation of the joystick within the trial 
duration, the screen was set to black for the remainder of the trial duration.  If the patient failed 





trials, patients who successfully inhibited response had their screen remain red for the remainder 
of the trial duration.  If inhibition was not successful, the screen was set to black for the 
remainder of the trial duration.  Also, if patients rotated the joystick in the direction opposite of 
the Instruction cue, that trial was removed from analysis.     
Segmentation of Task Data 
The recorded electrophysiological data for each session in this study was segmented 
using three different trigger events.  The events triggers included the instruction cue, the 
initiation of movement, and the stop signal cue.  Each event spanned 1 s before the trigger and 1 
s after.  We grouped the task data into four different types of trials.  These trial types were: “No-
Stop”, “MaybeStop-Go”, “MaybeStop-Stop-correct”, and “MaybeStop-Stop-fail”. 
The task consisted of 20% No-Stop (NS) trials and 80% MaybeStop (MS) trials (Figure 
5.1).  There were significantly more MS trials than “No-Stop” trials in this task in order to ensure 
a statistically relevant number of stop signal trials were presented to the patient.  Overall, 
patients were presented with approximately 60% Go trials and 40% Stop trials since MS trials 
consisted of MS-Go and MS-Stop trials.  In “No-Stop” trials, patients were instructed that the 
stop signal would not appear.  However in MS trials, patients were instructed that half of the 
trials in this type would have the stop signal appear.  Within MS trials, 50% of trials were MS-
Go and 50% were MS-Stop; in which the stop signal was presented to the patient at some 
variable SSD.  The SSD was dynamically adjusted from 100ms during the session in 50ms steps 
depending on if inhibition was successful or not. This allowed for approximately equal 






Figure 5.1: Stop-signal paradigm used intraoperatively with PD patients.  There were 2 groups of trial 
types: No-Stop and Maybe-Stop trials.  All trials were presented with the trial group printed to screen 1 
second prior to the instruction cue indicating either left or right rotation of the joystick for response 
movement.  Initiated movement was recorded between instruction cue and completed response ending the 
trial.  In MaybeStop-Stop trials the stop-signal was flashed on screen at a variable SSD.  Successful 
inhibition of joystick rotation kept the stop cue on screen until trial end.  Unsuccessful inhibition was 
recorded with the initiation of movement after the stop-signal appeared.  A blank screen appeared after 
response completions until the trial ended.     
Signal Processing and Statistical Analysis 
 
 Wideband data from MER within the STN were recorded for each session in a single 
continuous file sampled at 30 kHz for each patient (Matlab 2012, Mathworks).  Single unit 
activity (SUA) for each session was bandpass filtered from 500 to 2 kHz.  SUA wavelet filtered 
data was sorted for spikes over the duration of the task recording (Offline Sorter, Plexon; Dallas, 
TX).  Autocorrelograms of spike counts were used to ensure multiple units were not analyzed as 
one unit and firing frequencies were within physiological bounds.  SUA timestamps were synced 
with movement data and trial events recorded at 30 kHz from an analog joystick and an on 
screen photodiode (LiCor) respectively.   
 LFP activity for each session was extracted from wideband data from the single 





the LFP signal was decimated with a 1000th order finite impulse response anti-aliasing filter and 
downsampled to 500 Hz.  All data from 1 to 100 Hz were included in all analyses. 
 Gabor power spectrograms were computed to examine spectral power over time by 
convolving LFPs with Gaussian-tapered complex sinusoids of integer frequencies from 1 to100 
Hz and taking the squared magnitude of the resulting time-series.  The logarithms of the 
spectrograms were then averaged for each recording session. 
 Continuous measure of the theta, alpha, and beta power bands were calculated by zero-
phase-shift filtering of the LFP data between 2 – 6 Hz, 8 – 13 Hz, and 15 – 25 Hz using an FIR 
filter.  The filtered signal was Hilbert transformed to create the analytic signal and the magnitude 
of the signal was squared to provide a continuous measure of the power in the LFP frequency 
band of interest. 
 Significance for individual LFP band power for each session was determined by z-scores.  
Mean power for each band during trials was obtained by shifting timestamps corresponding to 
the trial-Begin event forward or backward in time by random interval between -1 and 2 seconds.  
The shift generated a random sample of local band powers during each trial, which were 
averaged to yield mean power for each band for a single iteration.  This procedure was repeated 
10,000 times to generate a distribution of mean powers for each band, from which the mean and 
standard deviations were calculated.   
Comparisons of power z-scores between trial types within a given session and frequency band 
were calculated using a two-sample paired t-test with a significance level of p < .001. 
Results 
 
 In this study, 3 PD patients undergoing DBS surgery were examined.  We simultaneously 
recorded SUA and LFP signals from 4 STN.  Recordings were electrophysiologically confirmed 
to be with the STN.  A total of 527 trials of the stop-signal task were performed with an average 
of 131 trials per session.  The average reaction time (RT) for all sessions was 621.75ms.  Table 
5.1 shows the count for each trial type and average stop signal reaction time (SSRT) for each 


















Recording 1 96 16 48 17 4 289 364 24 
Recording 2 95 16 47 15 3 287 376 29 
Recording 3 144 24 72 28 20 376 610 25 
Recording 4 192 32 96 44 17 684 1137 15 
Mean 131.75 22 65.75 26 11 409 621.75 23.25 
Table 5.1: Counts for each trial type, reaction time, and firing rate for each recording session.  SSRT was 
calculated by subtracting SSD from the median reaction time of “MaybeStop-Go” trials.  Reaction times 
were calculated from instruction cue onset to trial completion. 
The average SSRT for “No-Stop” trials in this study was 0.59 seconds while the average 
for “MaybeStop-Go” trials was 0.68 seconds (Figure 5.2).  The fastest SSRT was observed in 
“MaybeStop-Stop-fail” trials to be 0.46 seconds. 
 
Figure 5.2: Race model reaction times for movement trial types “MaybeStop-Stop-fail”, “No-Stop” and 
“MaybeStop-Go”. 
Theta Band Response 
Theta oscillations of the LFP signal increased significantly immediately after movement 
initiation for all “No-Stop” and “MaybeStop-Stop-fail” trials but not “MaybeStop-Go” trials 
(Figure 5.3A).  Trials of the “No-Stop” type had peak theta activity occur 310 ms after 
movement was triggered and was significantly greater than “MaybeStop-Go” trials (P = .005).    
The theta band showed significant increases to the presence of the stop signal; which was highest 
when response inhibition was unsuccessful (t = 0.44 s, P = .002).  A marked increase in theta 



























initiation (t = - 0.44 s, P = .016) compared to a significant decrease in theta activity for 
“MaybeStop-Stop-fail” trials prior to the start of movement (t = - 0.48 s, P = .014).   
 
Figure 5.3: Normalized z-score plots for triggered events for theta, alpha, and beta bands. A) Theta LFP 
response for all trial types. B) Alpha LFP response for all trial types. C) Beta LFP response for all trial 
types. 
Alpha Band Response 
 Alpha band oscillations were observed to be significantly increased in response to 
movement for all movement trial types (Figure 5.3B).  “No-Stop” trials had greater power 
increases in the alpha band compared to “MaybeStop-Go” trials, although peak power for the 
later trial type occurred 70 ms earlier.  Trials for unsuccessful response inhibition had a sustained 
significant increase in the alpha band for a 1 second period starting just before triggered 
movement with the peak in power 210 ms after movement trigger (P = .001).  Alpha oscillations 
also showed a significant increase in “MaybeStop-Stop-fail” trials but not “MaybeStop-Stop-
correct” trials to the presence of the stop signal (P < .001). 





 The beta band of the recorded LFP signals had significant decreases in activity 
throughout the duration of the “MaybeStop-Stop-fail” trials starting 400 ms before the 
instruction cue (P < .001) (Figure 5.3C).  Conversely, the “MaybeStop-Stop-correct” trials had a 
significant and sustained increase 500 ms before the instruction cue (P = .007).  When triggered 
on movement initiation, “No-Stop” trials had a significant increase in activity 180 ms after the 
trigger while “MaybeStop-Stop-fail” trials had nearly the exact opposite response in beta power 
at the same time (P = .002).  In response to the stop signal, “MaybeStop-Stop-fail” trials 
continued to have a significant decrease in activity compared to “MaybeStop-Stop-correct” trials 
(P < .001) (Figure 5.4).  “MaybeStop-Go” and “No-Stop” trials had similar responses in beta 
band activity until movement was initiated.  After movement, “MaybeStop-Go” continued to 
have no significant changes in beta response activity throughout the remainder of the trial 
duration.   
 
Figure 5.4: Scalogram plots from 5 Hz to 30 Hz for “MaybeStop-Stop-fail” and “MaybeStop-Stop-
correct” trial types centered on the Stop-Signal cue.  The top white boxes highlight the differences in 
power in the beta band.   The lower boxes show the differences in power between successful and 
unsucessful response inhibition in the alpha band. 
Single Unit Response 
 Single unit activity recorded simultaneously with LFP showed similar changes in firing 
frequency to LFP power in the beta band for response to stop signal inhibition.  Firing frequency 
on average was significantly lower for “MaybeStop-Stop-fail” trials compared to “MaybeStop-
Stop-correct” trials (P < .001) in the presence of the stop-signal (Figure 5.5).  There was a 





“MaybeStop-Go” trials just after the trigger.  Although the “No-Stop” trials had a slightly larger 
and earlier increase in firing rate (t = 0.14 s, f = 29 Hz, P < .001).  The “MaybeStop-Stop-fail” 
trials had an increase in firing rate just before the triggered movement and a firing rate larger 
than both “MaybeStop-Go” and “No-Stop” trials (t = - 0.04, f = 30.79 Hz, P < .001). Overall, 
firing rates for the “MaybeStop-Stop-fail” trials were significantly slower than the other trial 
types (P < .001). 
 
Figure 5.5: Average firing rate for the recorded single units across the three trigger events.  The trial 
types are represented by different colors, Black (“No-Stop”), Blue (“MaybeStop-Go”), Red (“MaybeStop-
Stop-fail”), Green (“MaybeStop-Stop-correct”). 
Discussion 
 
 In this study we confirmed previous findings of the role the STN has in response 
inhibition through the analysis of three main LFP frequency bands and SUA.  We recorded SUA 
and LFP activity simultaneously with microelectrodes in the STN during DBS surgery for 
Parkinson’s disease.  We correlated electrophysiological STN activity with an adapted stop-
signal task performed by patients intraoperatively.  We confirmed the significance of the STN in 
successful inhibition to movement by analyzing the theta, alpha, and beta bands of LFP and the 
changes in firing frequency of movement responsive neurons.   
We found that the STN had significant decreases in beta power and single unit firing 
frequencies in unsuccessfully inhibited movement trials compared to successful response 
inhibition in the presence of a stop signal.  This is consistent with recent studies identifying the 
STN as the primary “brake” in the basal ganglia; using inhibitory signals to regulate responses.2, 
4, 5, 16-20  Decreases in firing frequency and beta power triggered on the stop signal may suggest 





any changes in beta power after the instruction cue for successfully inhibited response trials.  
This may suggest that the inability of the beta band to return to baseline in failed inhibition trials 
is the result of an already programmed action for movement unable to be cancelled.  The beta 
band may control the cancellation of movement by maintaining a threshold of activity level as 
suggested in recent studies.1, 9, 21-24  These results further add to the role of the beta band in 
preparation and execution of movement. 
Theta activity appeared to be related to movement trials in the stop-signal task of our study.  
We observed an increase in activity for “No-Stop” and “MaybeStop-Stop-fail” trials triggered on 
movement initiation.  There was a significant difference in activity between the failed and 
successful response inhibition trials in the presence of the stop signal.    We confirmed that 
increases in theta STN activity were related to decision and movement cues described in recent 
studies using inhibitory tasks.6, 25, 26 
We did not observe any significant variations in the alpha band to the instruction cue for any 
trial types in this study.  There were increases in power related to movement for all response type 
trials as well as a significant increase of failed inhibition trials compared to successful stops.   
In our limited patient population, we did confirm that the race condition described by Logan 
and Cowan was met.7  As expected, the reaction times for failed stop trials were shorter than 
“No-Stop” trials which were shorter than the slowest reaction times of “MaybeStop-Go” trials.  
However, since the average reaction time for our patient population was considerably longer than 
that of normal subjects performing the stop-signal task; we cannot definitively confirm the 
electrophysiological characteristics of the STN in inhibitory control. Additionally in this study, 
we were constrained to using microelectrodes for recording electrophysiological data from 
within the STN.  Most recent studies have used DBS leads either intraoperatively or 
postoperatively externalized for performing stop-signal tasks with patients.  This enables the 
capability to record from multiple locations within the STN region, including the sensorimotor 
area, simultaneously in order to identify potential sites that may be task responsive.  We were 
limited to selected sites in the STN without the ability to discern the most optimal area for task 





Our findings provide further direct evidence and confirmation of the engagement of the STN 
in a task requiring movement inhibition.  The involvement and modulation of STN neuronal 
activity during response inhibition is evident in the main frequency bands of the LFP as well as 
single unit recordings from within the region.  These results from patients with PD should be 
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Chapter 6 : Conclusion 
 
The presented work demonstrates a substantial validation of the development of an 
intraoperative data acquisition system for use in deep brain stimulation surgery.  This system is 
of considerable use for both research and clinical applications.  IODA has been shown to 
improve clinical targeting of the STN using MR images and analyzed electrophysiological 
signals.  IODA has also enabled the structural mapping of the STN using local field potentials to 
properly identify optimal sites for chronic stimulation for the treatment of Parkinson disease.  
Additionally it was demonstrated that integration of experimental tasks for use intraoperatively 
was possible to confirm recent findings regarding the physiological role of the STN in movement 
control.  The development and subsequent broad validation of this system has enabled significant 
research to be possible during DBS surgery.  It has also proven to offer neurosurgeons with a 
wide range of experience to participate confidently and safely in brain stimulation procedures.   
This system is capable of being applied in other DBS surgical procedures and brain 
surgeries.  There is potential for IODA to be incorporated into DBS for Essential Tremor with 
stimulation in the ventrointermediate nucleus (VIM).  Both for clinical and research applications, 
IODA can potentially enable improved targeting of the VIM through the use of broadband MER 
signals and high resolution imaging.  There is significant impact on patient quality of care and 
DBS device longevity with research into alternative chronic stimulation parameters.  Until now, 
customizable stimulation parameters were not available and the possibility to explore stimulation 
with improved outcomes and reduced energy consumption was lacking.  IODA also has the 
potential to be applied into other types of clinical brain surgeries requiring precise localization.  
These surgeries include tumor excisions, DBS for depression, epileptic surgery, pallidotomy, and 
thalamotomy.   
A novel and highly adaptable intraoperative neural stimulation and recording system is 
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Hardware Setup Instructions 
 
1. Power the IODA rig: 
a. Plug in the white power cord on the outside of the IODA rig. 
b. Open the back cover of the IODA rig and turn on the power strip at the bottom. 
c. Turn on the D360 amplifier. 
d. Close the back cover. 
  
Side of the IODA rig. 
 








Front side of the IODA rig. 
 
2. Connect IODA to external hardware. On the front side of the IODA rig: 
a.  Connect the microTargeting remote control to the 
microTargeting Controller unit. Locate the motor, 
but do not connect it to the Controller.  The motor 
will be connected in a later step. 
b. Turn on the IODA PC and plug in the mouse 
and keyboard (stored beneath the PC) into the 
two front USB jacks. 
c. The IODA rig has two external DVI outputs 
above the white power cable. Using the DVI 
cable stored beneath the PC, connect the top 
DVI output to the nearest wall-mounted 
external display. 
d. Turn on the monitor mounted on the top of the 
IODA rig and reorient to face the front of the 
IODA rig. 
 









e. Using the oval remote found near the MTC, 
click buttons 1 and 14, pointing the remote at 
the 4x4DVIDLMatrix next to the MTC.  
Note: If the DVI cable is connected to the lower 








3. Set up the Faraday cage: 
a. Carefully pull the Faraday cage from the IODA rig and place on a non-conducting 
surface. Note: A blanket, stored beneath the PC, can be placed under the cage to 
insulate it from a conducting surface. 
b. Orient the unused opening of the Faraday cage toward the patient. 
c. Check that the RECORD adaptor is plugged into Input 1 of the D360 head stage, 
with the green connector in the COM jack, the red connector in the blue jack, and 
the black connector in the red jack. 
  
Inside of the IODA Faraday cage. 
 
The D360 amplifier head stage. 
 
 








1. Log onto the IODA PC. 
2. Check PC volume, adjusting volume through Windows or speaker volume knob as needed. 
Volume should be clearly audible to the surgeon. Note: the PC speaker is located next to the 
microTargeting Controller unit. 
3. Navigate to  C:\Users\IODA\Desktop\OR SOFTWARE . 
4. Open the D360 client.  
5. Open the IODA GUI. Note: opening the IODA GUI will also open Neurosuite and the ET patient 
interface. 
D360 client initialization 
 
Note: These steps must be performed after turning on the D360 amplifier system. 
1. Change window focus to the D360 client. 
 
2. Check that all eight inputs are displayed as shown above. 
a. Initialization of settings is automatic. 
Note: no items will be shown in the window if initialization fails. If initialization fails, 
check that the D360 is powered on and the head stage is plugged in, then close and 
reopen the D360 client. 
 
3. Minimize the window. 








1. By default, the IODA GUI opens to the Initialization tab. If the Initialization tab is not 
selected, navigate to it by clicking on its tab. 
 
2. Select the Case Type and enter the Patient ID and Track. 
a. Case Type options: STN (Parkinson’s disease), VIM (essential tremor), C25 
(major depression), and Test 
b. Patient ID is a combination of the patient’s first and last initials and the last four 
digits of their UMHS ID. Example: for patient John Smith, UMHS ID 987654321, 
enter JS4321. 
c. Track indicates the side (RT or LT) and attempt number on each side. Examples: 
LT1 for the first left-side track, RT2 for the second right-side track. 
 
3. Choose whether to Save Data. By default, Save Data is turned on. 
 
4. Select the appropriate functionalities. By default, DAQ (for MER) and Depth (for MTC) 
are turned on. 
a. For ET cases, turn on Stim. 








1. By default, Neurosuite opens to the Initialization tab. If the Initialization tab is not 
selected, navigate to it by clicking on its tab. 
 
2. Click on the folder icons to the right of the MRI Image and CT Image File Path fields 
to browse to the appropriate imaging files. 
a. Image files will be provided by the neurosurgeon on a USB flash drive. 
b. MRI image files will typically be denoted by a “3TC” in the file name. 
 
3. Hit CTRL+R to run the Neurosuite module. 
 







Note: if no image has appeared after files have completed loading, right click on the images and 
select Zoom to Fit. 
5. Using the blue slider bar, select to an appropriate transverse slice on which to select 
fiducial coordinates. Note: the slice with the longest AC-PC line is typically used. 
 
6. Using the crosshair tool (shown right) to the left of the slider bar, select 
fiducial #1 (bottom of the right side). Then click on the 1 button adjacent to 
the image. 
 
7. Proceed clockwise around the image, selecting fiducials with the crosshair 
and clicking on the corresponding number button until all nine fiducials have 
been selected. (The bottom three are unused.) 
 
Note: The magnifying glass tool, also found on the tool strip shown right, can 
be used to better pinpoint fiducial coordinates. Dragging the crosshair near 
the edges of the image scrolls the image when zoomed in. 
 
8. Once all fiducials have been selected, hit the STOP button to stop the VI. All 







Connecting to the Patient 
 
1. Connect to the patient: 
a. Attach the REM Polyhesive Adult Patient Return Electrode (usually connected to 
the Bovie) to the red male connector in the Faraday cage. 
b. When the neurosurgeon presents the MER signal cable, connect it to the 
RECORD adaptor attached to the D360 head stage. 
2. Connect the microTargeting motor: 
a. When the neurosurgeon presents a plastic sheath, remove the microTargeting 
motor’s cap and place the motor in the plastic sheath. 
b. Extend the sheath and attach the adhesive end to the side of the IODA rig. 
c. Plug the microTargeting motor into the microTargeting Controller. 
d. Turn on the microTargeting Controller by flipping the switch on the back of the 
unit (near the top of the unit). 
e. Click the button on the front of the microTargeting Controller to zero the unit. 
Note: Do not click the button again after zeroing the Controller. 




REM Polyhesive Adult Patient Return 
Electrode connector (right) and red and black 







Intraoperative Monitoring and Recording 
 
After setup and initialization are complete, bring the IODA GUI window into focus and hit 
CTRL+R to being recording. Intraoperative monitoring can be performed on the Signal Analysis 
tab. 
Initialization checklist: 
• The D360 amplifier system is turned on and the D360 client software was initialized after 
turning on the hardware unit. 
• The microTargeting Controller is turned on and zeroed, with motor and remote control 
plugged in. 
• The REM Polyhesive Adult Patient Return Electrode is connected in the Faraday cage. 
• Patient name and ID, case type, and track are entered in the IODA GUI. 
 
At the top of the IODA GUI is the primary signal display. The filtered, gain-removed 
microelectrode recording is shown here. Filter settings can be adjusted in the Filters tab. 
Beneath the primary signal display are the Volume Slider, Mute button, Pause button, and 
STOP button. The STOP button performs a soft stop of the VI when pressed and held down. If 
this button fails to completely stop the VI, use the hard stop afterwards with CTRL+period.  





MRI Observation in Neurosuite 
 
Note: Neurosuite will automatically run if MRI is turned on during initialization. 
 
MRI observation can be performed on the Observation tab in Neurosuite. 
Note: if no images have appeared after files have completed loading, right click on the images 
and select Zoom to Fit. 
1. Enter target frame coordinates and then the ring, arc, and length in the appropriate fields 
at the top right of GUI (above the transverse image). Note: Entry coordinates are 
automatically calculated from the above parameters. 
 
2. The crosshair tool and blue slider bars can be used to select slices to view. The crosshair 
indicates the same voxel in all three views. The magnifying glass tool can be used to 
zoom in on images. 
 
3. Turn on Track MTC to track the probe along its track. Note: when Track MTC is turned 
on, slices can no longer be manually selected for viewing. 
 






Controlling Probe Depth 
 
Note: the following features will only function if Depth was turned on during initialization. 
 
Probe Depth controls and displays are found near the top right corner of the IODA GUI. 
1. To Advance: 
a. Enter a step distance in the Distance (mm) field. 
b. Hit Advance to advance the motor. 
c. Hit Stop Motor to stop the motor at any time. 
 
2. To Auto Advance: 
a. Enter a step distance in the Distance (mm) field. 
b. Enter a target depth in the Target (mm) field. 
c. Turn on AUTO. 
d. Hit Advance to begin advancing the motor. 
e. Hit Stop Motor to stop the motor at any time. 
 
3. To move backwards: 






Note that the microTargeting remote control can also be used to control probe depth when not 








Note: the following features will only function if Stim was selected during initialization. 
 
Stimulation controls and displays are found on the Stimulation tab. The DS4 stimulator unit is 
found inside the Faraday cage. 
 
1. Prior to stimulation, hit the Mute button to mute MER signals. 
 






3. Turn on the Gate switch on the DS4. 
 
4. Select between macro and microstimulation: 
a. To apply MACROSTIMULATION: 
i. Plug the macrostim adaptor to the DS4 output. Plug the green connector to 
the black output of the DS4 and the red connector to the red output of the 
DS4. 
ii. Select 10mA on the DS4 Output dial. 
iii. Select the MACRO option on the Stimulation tab. 
b. To apply MICROSTIMULATION: 
i. Plug the microstim adaptor to the DS4 output. Plug the black connector to 
the red output of the DS4 and the red connector to the black output of the 
DS4. 
ii. Select 100µA on the DS4 Output dial. 
iii. Select the MICRO option on the Stimulation tab. 
 
5. Disconnect the MER cable from the D360 amplifier and connect the MER cable to the 
adaptor. 
 
6. Select between gated and ungated stimulation: 
Note: the gate switch on the DS4 should be ON for both gated and ungated stimulation. 
a. To apply GATED stimulation: 
i. Plug the Gate Signal cable to the DS4 Gate input. 
ii. Select the GATED option on the Stimulation tab. 
iii. Check settings in the Gated Settings tab (within the Stimulation tab). 
Note: only square waves can be output with gated stimulation. 
b. To apply UNGATED stimulation: 
i. Unplug the Gate Signal cable from the DS4 Gate input. 
ii. Select the UNGATED option on the Stimulation tab. 
iii. Check settings in the Ungated Settings tab (within the Stimulation tab.) 
 
7. Apply stimulation: 
a. Select the Stimulation Amplitude using the slider or by entering a value into the 
digital display. 
b. Click STIM to apply stimulation. Click again to stop stimulation. Pulse train can 
be used to apply stimulation for a preset period. 
Note: A green Stimulation icon will light up and an audio tone will play when 








After DBS probe placement is confirmed, the IODA system can be powered down, 
disassembled, and returned to the research laboratory. 
1. Shut down the IODA PC: 
a. Check that the IODA interface has been stopped. 
b. Shut down the IODA PC. 
c. Detach keyboard and mouse. 
d. Store keyboard and mouse underneath IODA PC. 
e. Detach DVI cable from external display and external output. 
f. Coil DVI cable and store underneath IODA PC. 
g. Reattach original DVI cable to external display. 
 
2. Store the Faraday cage: 
a. Detach the MER signal cable from adaptors in the Faraday cage and remove from 
the Faraday cage. 
b. Detach the Red Cable from the D360 head stage, if used, and remove from the 
Faraday cage. 
c. Turn off the DS4, if used. 
d. Replace the lid on the Faraday cage. 
e. Slide the Faraday cage into the empty shelf in the IODA rig. Orient the cage such 
that cables exit the Faraday cage on the right hand side. 







3. Power down the IODA rig: 
a. Shut off the microTargeting Controller with the switch on the back of the unit. 
b. Shut off the D360 amplifier with the switch on the back of the unit. 
c. Shut off the power strip, located behind the back panel of the IODA rig. 
d. Unplug the IODA rig and store power cable on the rig’s external handle. 
 
4. Store the microTargetting Controller: 
a. Unplug the microTargeting motor and remote control from the microTargeting 
Controller. 
b. Store the microTargeting remote control next to the Controller unit. 
c. Ask the surgeon to detach the microTargeting motor from the patient. 
d. Remove the microTargeting controller from the plastic sheath. 
Note: The use of gloves is recommended for this step, as the sheath and motor 
may have had contact with patient fluids. 
e. Replace the cap on the microTargeting motor. 






Known Issues and Troubleshooting 
 
Runaway probe movement: 
Failure to zero the microTargetting Controller prior to running the IODA VI will cause the motor 
to advance until the controller unit is shut off. The motor cannot be controlled using either the 
software controls or the physical remote control when this occurs. After shutting off the 
controller unit, the motor must be manually returned to its zero position before resuming. 
Signal saturation: 
Signal saturation is indicated by prolonged observation of low-amplitude noise (~25 µV) with no 
movement artifact during motor movement. After hitting MUTE on the IODA interface: 
1. Have the surgeon attach a sterilized Red Cable to the external cannula with the alligator 
clip end. Plug the other end into the blue input of the D360 head stage, in place of the 
MER adaptor’s red connector. Check for signal restoration. 
2. If Step 1 fails to restore signal, have the surgeon clip the Red Cable to the retractor on the 
patient. Check for signal restoration. 
3. If Step 2 fails to restore signal, plug the black male connector in the Faraday cage into the 
REM Polyhesive Adult Patient Return Electrode connector. Check for signal restoration 
with the Red Cable clipped to the external cannula and to the retractor. 
 
 
 
